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ABSTRACT
TRANSIENT DISPLAY OF CHIMERIC PROTEINS ON BIOLOGICAL SURFACES
AS AN EFFECTIVE STRATEGY FOR MODULATION OF INNATE AND
ADAPTIVE IMMUNE RESPONSES
Pradeep Shrestha
April 8, 2020
The major premise of this dissertation was to transiently display novel
immunological ligands on biological membranes as a localized means of modulating innate
and adaptive immune responses with applications to bone marrow and pancreatic islet
transplantation. In Chapter two, we engineered donor allogeneic bone marrow cells to
transiently display a novel form of FasL, SA-FasL, to efficiently purge out alloreactive
donor T cells to prevent acute GVHD. In Chapter three, we engineered pancreatic islets
with a novel form of CD47, SA-CD47, to modulate instant blood mediated inflammatory
reaction (IBMIR) to prevent immediate islet graft loss following intraportal
transplantation.
GVHD is initiated and perpetuated by mature T cells in the bone marrow inoculum
following transplantation into conditioned recipients. Upon activation, T cells upregulate
Fas receptor and become sensitive to FasL-mediated apoptosis. Thus, we hypothesized
that the display of SA-FasL on T cells in bone marrow will result in their apoptosis
potentially in autocrine fashion following activation in response to recipient alloantigens
and engagement of Fas with SA-FasL on the T cells, thereby resulting in the prevention of
v

acute GVHD. We demonstrated that SA-FasL engineered T cells underwent apoptosis
following response to alloantigens both in vitro and in vivo. Most importantly, in an
haploidentical rodent setting where C57BL/6 bone marrow cells containing T cells
transplanted into lethally irradiated F1 recipients, engineering cells with SA-FasL resulted
in the prevention of lethal acute GVHD in 80% of recipients long term (>100 days). We
extended this observation to xenogeneic acute GVHD setting, where mice receiving SAFasL-engineered human PBMCs were significantly protected.
Significant islet mass loss following intraportal transplantation is a major barrier
for clinical islet transplantation. IBMIR is initiated and perpetuated by innate immune cells.
CD47-SIRPα axis known as innate immune checkpoint delivers “don’t eat me signal” to
prevent phagocytosis and activation of myeloid cells. Thus, we hypothesized that
engineering islets to transiently display SA-CD47 as an innate immune checkpoint will
mitigate IBMIR and enhance engraftment following intraportal transplantation. In a
syngeneic marginal mass model of intraportal transplantation, SA-CD47-islets showed
better engraftment and function as compared with the control group (87.5 vs 14.3%).
Engraftment was associated with low levels of intrahepatic inflammatory cells and
mediators of islet destruction, including HMBG-1, tissue factor, and IL-1β. Overall, we
show that transient display of immunological ligands on biological membranes is effective
in modulating innate and adaptive immune responses with significant translational
implication for multiple immune-based disorders.
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CHAPTER 1: INTRODUCTION

Overview on hematopoietic stem cell transplantation (HSCT)
Hematopoietic stem cells or bone marrow transplantation is a well-established
treatment care for hematologic and non-hematologic malignancies that are not curable by
conventional treatment procedures1,2. Over the last 50 years, HSCT procedure has evolved
from a highly experimental technique to an effective cellular immunotherapeutic treatment
against a number of malignancies, metabolic deficiencies, and autoimmune diseases3,4.
With advances in patient-donor selection, reduced toxicity conditioning regimen, stem cell
sources and supportive care, HSCT procedure has seen a significant progress. Annually an
estimated 50,000 procedures are done worldwide and more than 1 million transplantations
have been performed with 40% being allogeneic in nature2,5.
The HSCT may be autologous or allogeneic in nature. Autologous transplantation
procedure involves infusion of patient’s own stem cells. The procedure is mainly
performed as a strategy to rescue from lethal chemotherapy against underlying malignancy.
Allogeneic transplantation, where immunologically disparate hematopoietic stem cells and
immunologic repertoire are infused into irradiation or chemotherapy conditioned patient to
establish donor derived hematopoiesis and immunity6. Allogeneic transplant modality is
currently extended to maintain mixed donor chimerism to establish solid organ graft
tolerance7-9. Despite the advances, allogeneic HSCT is associated with a major life-
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threatening complication, graft-versus-host disease (GVHD), thus limiting the use of this
important procedure. GVHD occurs when the immunocompetent donor cells in the graft
recognizes the recipient as foreign. The resulting immune response activates donor T cells
to attack and eliminate recipient cells as foreign antigen bearing cells2.
There are two main clinical presentation of GVHD: acute and chronic GVHD with
different etiologies and pathophysiology. Acute GVHD was initially defined as a condition
appearing within 100 days post transplantation whereas chronic GVHD being later1,10.
However, this distinction is not tenable anymore as acute GVHD may present beyond 3
months, whereas chronic GVHD may contract within 100 days post transplantation. The
present diagnosis criteria involve the specificity of sign and symptoms, rather than the time
of onset11,12. Acute GVHD manifests as infiltration of inflammatory T cells with target
tissue destruction particularly skin, gastrointestinal tract, and liver. On the other hand,
chronic GVHD involves the Th2 immune response, autoimmune disease characteristics
including autoantibody formation in skin and mucosal surfaces. Acute GVHD is primarily
driven by activated T cells and pro-inflammatory cytokines, whereas chronic GVHD is
more complex and involving the interaction of innate immune cells with dysregulated B
and T cells2,13.

Immunobiology of acute graft-versus-host disease
Acute GVHD is a severe inflammatory complication of allogeneic HSCT. Despite
the advance in preventive and post-transplant strategies, acute GVHD is still considered a
significant cause of morbidity and mortality in allogeneic HSCT recipients. Billingham
proposed three distinct requirements for GVHD reaction: i) immune responsive donor cells
2

in the graft; ii) Antigenic disparity between donor and recipient; iii) immune suppressed
recipient system that cannot eliminate transplanted donor cells12,14. It is now well
established that immune competent cells are donor T cells that primarily drive GVHD and
can occur in different clinical settings when tissue (bone marrow, blood products or solid
organ) containing T cells are transplanted to recipient that is unable to eliminate those
cells2,12,15.
Three-phase model of acute GVHD
The progression of acute GVHD can be summarized in a three step process with an
afferent and efferent phase. Phase 1 involves the effect of conditioning in which irradiation
and chemotherapy as conditioning regimen induces injury to host epithelium and
endothelium generating proinflammatory cytokines and recruits innate immune cells.
Phase 2 involves the process of allorecognition, activation and proliferation of donor T
cells in the inflammatory milieu induced in phase 1. These two phases make afferent phase
of acute GVHD. Whereas in phase 3 as efferent phase the activated multiple effector cells,
cytotoxic T cells (CTLs), natural killer (NK) cells and large granular lymphocytes cause
significant damage and further injury in specific and non-specific ways12,16,17. The threephase model of acute GVHD is summarized in figure 1.
Phase 1: Effects of conditioning
HSCT recipient undergoes conditioning regimens before transfusion of donor
grafts. The procedure involves irradiation and/or chemotherapy. The conditioning therapy
is rather toxic to recipient tissues and induces tissue damage. Underlying disease and
conditioning induce tissue injury and respond by releasing proinflammatory cytokines
(TNF-α, IL-1 and IL6).
3

Figure 1: Pathophysiology of acute GVHD. The three phases of acute GVHD. 1.
Activation of host APCs because of tissue damage due to conditioning regimen. 2.
Activation, differentiation and proliferation of donor T cells by host APCs. 3. The effector
phase where complex cascade of effector cells and inflammatory mediators in presence of
chemokines and cytokines mediate host tissue damage. (Adapted from Ferrara et. al.
Lancet 2009).
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The proinflammatory cytokines upregulates the expression of chemokines and other
adhesion molecules, MHC antigens, costimulatory molecules in antigen presenting cells
(APCs)2,12,18,19. In addition, gastrointestinal tract is particularly susceptible to injury during
the conditioning process. This leads to systemic infusion of inflammatory stimuli such as
lipopolysaccharide or other pathogen associated molecular patterns that stimulates gut
associated lymphocytes and macrophages to produce TNF-α and IL-1. This directly
contributes to “cytokine storm”2. Alongside, danger signals such as ATP, uric acid, high
mobility group box-1, heparan sulfate released during tissue damage can activate
inflammasomes2,20. This leads to cleavage of pro-IL-1β to its bioactive form IL-1β and thus
enhancing GVHD. This surge of cytokines along with danger signals is important for
initiation of primary and secondary immune response. Direct correlation between intensive
conditioning regimen and acute GVHD severity is well established and clinical studies
suggests that reduced intensity conditioning is associated with significantly reduced
morbidity and less early acute GVHD17,21.
Phase 2: Activation of donor T cells
Interaction between donor T cells and recipient APCs play central role in acute
GVHD. This interaction leads to their subsequent activation, proliferation and
differentiation and is the second afferent stage in progression of acute GVHD. Donor T
cells can be activated directly by host derived or indirectly by donor derived APCs.
Presentation of alloantigens directly by host APCs appear to be critical in inducing acute
GVHD although indirect presentation by recipient APCs also plays role in activation of
donor T cells22,23. Dendritic cells (DCs) are the potent APCs during the process.
5

Inflammatory cytokines (TNF-α, IL-1), danger associated molecular patterns (DAMPs)
and pathogen associated molecular pattern (PAMPs) produced during phase 1
(conditioning effects) play important roles in maturation of DCs and induce activation of
donor T cells whereas immature DCs induce T cell tolerance2,12,24.
In addition to engagement of suitable TCR to alloantigen presenting MHC
molecule, second costimulatory signal is required for full activation of T cells.
Costimulatory signals lower the T cell activation threshold, inhibit apoptosis signaling,
maintain cytokine production and support the metabolism of effector T cells. Multiple costimulatory pathways including ICOS, CD28, OX40, and 41BB2,25,26 and negative
regulatory pathway including CTLA-4, PD1-PDL1, have been shown to regulate
progression of acute GVHD26,27.
Finally, cytokines play important role in maintenance of T cell activation and
survival that drives acute GVHD. Multiple cytokines including IL-1β and Th1 cell
cytokines (IFN-γ, IL-2 and TNF-α) mediate T cells differentiation and GVHD
pathogenesis12. For instance, IFN-γ plays a crucial role in pathophysiology of acute GVHD.
T cells isolated in experimental and clinical acute GVHD produce large amounts of IFNγ28. IFN-γ upregulates chemokine expression, MHC molecule and adhesion molecules such
that it facilitates antigen presentation and effector recruitment17. Also, IFN-γ plays
important role in regulating apoptotic death of activated T cells by regulating Fas receptor,
thus regulating GVHD29-31. In addition, IFN-γ exposure significantly reduces the threshold
of LPS required to production of proinflammatory cytokines and Nitric oxide (NO) by
macrophages17,32.
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Phase 3: Cellular and Inflammatory effector phase
Multiple cellular and inflammatory mediators mediate host tissue damage during
the effector/efferent phase. It is a complex cascade where inflammatory agents (eg. NO.
TNF-α, IL-1) and cellular mediators (eg. Cytotoxic T cells, NK cells) work in synergy to
amplify host tissue damage thus promoting inflammation and target tissue injury. The
primary cellular effectors are CTLs and NK cells that mediate direct tissue damage33. They
can mediate cytotoxicity by two main pathways. Contact dependent ligation of Fas-FasL
results in activation of death-inducing signaling complex (DISC). Activation of DISC
results to activation of caspases ultimately leading to apoptotic cell death34-36. During
GVHD, hepatocytes, epithelial cells on bile ducts upregulate expression of Fas receptor
making them susceptible to FasL mediated cytotoxic effect. In contrast, gastrointestinal
damage is preferentially mediated by perforin-granzyme-B cytotoxic pathway37,38.
Activated mononuclear phagocytes are major source of inflammatory mediators
including TNF-α, IL-1 that promote direct tissue damage in acute GVHD. TNF-α plays a
central role in pathogenesis of acute GVHD. It plays role in activation of DCs and promotes
antigen presentation. Also, regulates the recruitment of effector cells (neutrophils,
monocytes, and effector T cells) to target organ by induction of inflammatory chemokines
(CCL2-CCL5, CXCL2, CCL17)12,17. In addition, TNF-α can induce apoptosis and necrosis
directly on tissues33,39. Nitric oxide (NO) is another inflammatory mediator in acute
GVHD. NO promotes pathophysiology of acute GVHD by inducing immunosuppression
an inhibiting repair mechanism of target tissue. This results in inhibition of proliferation of
epithelial stem cells in gut and skin and induction of direct tissue damage32,40,41.
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Thus, the complex synergistic interaction between cytotoxic effector cells and
inflammatory mediators in presence of chemokines and cytokines results in amplification
of local tissue injury thus further promoting inflammatory response that ultimately results
in observed tissue destruction in the transplant recipient.

Preventive and therapeutic strategies against acute GVHD
Cyclosporine-A, a calcineurin inhibitor and a cytotoxic agent methotrexate (MTX)
or mycophenylate mofetil (MTF) are commonly used as standard preventive
pharmacologic agents against acute GVHD by multiple clinical centers. MTX/MTF and
cyclosporine exert their antiproliferative effect on activated donor T cells by interfering
with purine synthesis and calcium dependent TCR signaling respectively. With discovery
of tacrolimus, another calcineurin inhibitor with similar mechanism to cyclosporine-A, that
has similar or superior efficacy to cyclosporine is now widely used in clinical HSCT2,12,15.
Tacrolimus/ cyclosporine exert their effect by inhibiting the calcineurin that is required for
the activation of nuclear factor of activated T cell (NFAT) family transcription factor that
is required for transcription of IL-2 and activation of T cells42. Sirolimus, an mTOR
inhibitor, is more potent inhibitor of activation and proliferation of conventional T cells
than regulatory T cells (Treg cells) owing to dependence of conventional T cells on mTORkinase B. High dose of cyclophosphamide is currently used in haploidentical HSCT
settings. Two doses of cyclophosphamide are infused immediately post transplantation to
eliminate highly proliferating alloreactive T cells but concomitantly sparing of stem cells
and Treg cells. Expression of high level of aldehyde dehydrogenase in Treg cells and stem
cells is a major in vivo mechanism to cyclophosphamide resistance43.
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Besides the use of pharmacologic agents, manipulation of donor T cells as a
prophylactic strategy has been employed in multiple experimental and clinical HSCT
settings. One such strategy employs T cell depleted bone marrow graft transplant followed
by delayed donor lymphocyte T cell infusion44-46. Delayed T cell add back strategy
circumvented acute GVHD and restored graft-versus-leukemia (GVL) effect; however, the
antileukemic effect was not as efficient as T cell replete transplants44. Another strategy
involves T cell depletion from the graft. These methods include ex vivo negative selection
(e.g. monoclonal antibody, lectin agglutination), ex vivo positive selection of CD34+ cells,
or in vivo depletion (anti T cell antibody preparation). However, these strategies
substantially limited acute GVHD incidences but did not translate to improved overall
survival because of graft failure, Epstein-Bar-Virus associated lymphoproliferative
disorder, and disease relapse2,45,47. A more subtle strategy to define anti-host GVHD
causing T cells and their depletion have been reported. This strategy targets activation
induced antigens; whose expression is upregulated on alloreactive T cells upon stimulation
in allogeneic mixed lymphocyte reaction culture. Selective depletion of activated cells
based on activation markers (such as CD25, CD69, HLA-DR, CD134 and CD137) using
fluorescence activated cell sorting (FACS) or CFSE dilution48 or CD25 conjugated
immunotoxin49 have been reported to improve the outcome of HSCT47,48,50,51. These
specific alloreactive T cell depletion approach significantly reduces GVHD without losing
T cell associated graft-supporting properties and early immune reconstitution50,52.
Multiple cellular therapy approaches have been tested. Adoptive transfer of ex vivo
expanded Treg cells along with T cell replete graft was associated with significantly
reduced incidence of acute GVHD with better survival53. In addition, adoptive transfer of
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donor lymphocytes co-cultured with IL-10 treated host APCs in presence of TGF-β to
enrich IL-10 producing type 1 regulatory T (Tr1) cells showed enhanced immune
reconstitution with reduced acute GVHD2.
Despite the prophylaxis, acute GVHD still evolves and the first line of therapy is
systemic glucocorticoids like prednisone that have potent anti-lymphocyte and antiinflammatory activity. Patients refractory to steroid treatment have dismal long term
prognosis with overall survival rate of only 5-30%2. More importantly, acute GVHD
restrict the HSCT to haploidentical population. Thus, there is an acute need for the
development of less toxic and more efficacious approaches for bone marrow
transplantation that goes beyond haploidentical.
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Type 1 diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by persistently
increased blood glucose level (BGL). The higher BGL in an individual being defined as
fasting glucose level ≥ 125 mg/dl or random non-fasting glucose level ≥ 200 mg/dl or
hemoglobin A1c (HbA1c) ≥ 6.5%54,55. Persistent higher BGL can cause ketoacidosis,
vascular injury, kidney failure, heart disease, stroke and blindness. The world prevalence
of diabetes in adults was 6.4% in 2010 and expected to rise to 7.7% by 203055. Every year
diabetes is associated with 200,000 deaths and costs $245 billion in US alone56.
Type 1 diabetes (T1D) is a classical T cell mediated autoimmune disorder
associated with loss of pancreatic β-cells. Significant loss of β-cells leads to insulin
deficiency resulting in hyperglycemia and ketoacidosis54. Although it is termed as
“juvenile diabetes” due to more frequent diagnosis in children, majority of patients with
T1D are adults and represents 10-15% of total diabetes mellitus cases worldwide.
Annually, in average 78,000 youths are diagnosed with T1D worldwide and in US alone >
20 cases per 100,000 people and the incidence rate is expected to rise56-58.
Etiology of T1D
T1D is a polygenic heritable disease and at least 20 different chromosomal regions
are associated to its susceptibility. For instance, identical twin concordance rate of T1D is
30-70%, sibling risk of 3-7% and risk of 1-9% for children with parents who have T1D59,60.
Multiple genetic factors contribute to both susceptibility as well as resistance to
precipitation of T1D. One of the largest contributions comes from several genes located in
MHC complex on chromosome 6p21 (i.e IDDM1 locus). Two HLA class II haplotypes
HLA-DR3/4-DQ2/8, involved in antigen presentation, are associated with high risk or
11

disease heritability, whereas HLA-DR2-DQ6 allele is protective57,59-61. Genome-wide
association studies have identified multiple non-HLA alleles, VNTR, PTPN22, CTLA4,
IL2RA, associated with susceptibility to T1D. These genetic variants are involved in
immune response that contributes to dysfunctional immune responsiveness, including
development and maintenance of tolerance60. Despite the genetic factors, the concordance
rate of T1D among monozygotic twins is only 50%, implicating the potential role of
environmental factors in development and precipitation of T1D. One of the major
candidates is viral infection. Extensive data suggests coxsackieviruses, an enterovirus
infection precipitates T1D62. With evidence of enterovirus in pancreas of recent onset T1D
patients and epidemiological studies suggesting significantly more enterovirus infection
among diabetic patients than in controls supports the notion that viral infections are the
environmental triggers. Many viruses can cause chronic or latent infection. Direct evidence
comes from a study where coxsackievirus can infect β-cells and cause insulitis and diabetes
in murine models63. With the landmark finding by Foulis et al.64 it is suggested that β-cell
tropic viral infection upregulates HLA class I and IFN-α as “viral molecular signatures”.
In addition, significant sequence similarity between coxsackievirus protein 2C and
glutamic acid decarboxylase (GAD) protein, a major T1D autoantigen, postulates the viral
mimicry as an etiology of T1D65. Coxsackievirus induced upregulation of CXCL10
chemokine on pancreatic islets plays important role in recruitment of CXCR3 positive
autoreactive T cells following viral infection66. Cumulatively, available data suggest the
significant role of environmental triggers, viral infections, microbiome composition and
metabolites, milk and wheat proteins, in unleashing autoimmunity, leading to destruction
of beta cells that ultimately results in T1D.
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Silent immune events targeting the destruction of pancreatic β-cells may take years
before clinical symptoms of T1D becomes apparent. Autoantibodies and activated
autoreactive T cells infiltrate the pancreas to destroy insulin producing β-cells. The
persistent destruction of pancreatic β-cells is a slow process and may become undetectable
until the majority (>80%) of pancreatic islets are destroyed or rendered dysfunctional,
making an individual hyperglycemic and dependent on exogenous insulin54,62. CD8+ T
cells are the predominant population in the insulitis region, followed by macrophages,
CD4+ T cells, and B cells.
Van Belle TL et al.62 proposed that the disequilibrium between immune
suppressive mechanisms (Treg cells) and autoreactive T cells occur over time and shifts
the balance to islet autoimmunity, leading to significant loss of islets mass and T1D
(Figure 2). CD8+ T cells mediated killing of beta cells, by release of perforin and
granzyme or Fas-FasL dependent interaction, is likely the central mechanism of beta cell
destruction. CD4+ T cells likely contributes to activation of B cells and CD8+ T cells by
secretion of cytokines (IL-21) or by positive feedback mechanism (CD40-CD40L)62,67.
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Figure 2: Progression of type 1 diabetes. (Adapted from Van Belle TL et al. 2011.)

Medical management of T1D
Once T1D is diagnosed, the main objective is to maintain the BGL near normal
level. Insulin remains the mainstay of the therapy although insulin analogs are available to
manage BGL. Frequent glucose monitoring and multiple dose insulin regimen is required
for optimal glycemic control. Multiple insulin injections or insulin pumps have their own
complications and are limited to controlling medical complications, including hyper or
hypoglycemia and vascular injury54. Hypoglycemia and ketoacidosis are potentially lifethreatening complications. Genetic predisposition with serological evidence for multiple
autoantibodies is enough to predict the susceptibility of T1D. Multiple preventive strategies
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that target autoimmune responses are being tested to prevent progression of T1D. Most
strategies broadly implement immunomodulatory agents to maintain tolerance.
Nevertheless, it is still at the primacy for prevention and reversal of T1D with no
therapeutic agents being approved59,68,69. Following the breakthrough protocol for islet
transplantation, the procedure has become standard of care treatment for individuals who
have developed end-stage renal failure. Pancreatic islet transplantation involves infusion
of donor islets into the liver via portal vein.
Pancreatic islet transplantation
Pancreatic islet transplantation (PITx) involves isolation of islets (containing β cells
along with other endocrine and non-endocrine cells) and infusion into the liver of recipient
via hepatic portal vein. Since the first islet transplantation was performed two decades ago,
PITx is now considered safe and real therapeutic option for patients with chronic
pancreatitis (autotransplantation) or in selected patients with affected by T1D
(allotransplantation)70,71.
Chronic pancreatitis is a syndrome with progressive inflammatory condition in
pancreas leading to permanent damage leading to impaired endocrine and exocrine
function72. This disease is the result of multiple environmental and genetic factors and
involves replacement of pancreatic secretory parenchyma by fibrous tissue. Chronic
pancreatitis is debilitating, painful, and eventually leads to diabetes. Total pancreatectomy
followed by auto islet transplantation is performed to eliminate pain of pancreatitis and
mitigate resultant pancreatogenic diabetes. So far more than 500 islet autotransplantation
have been performed for cases of chronic pancreatitis. The procedure involves complete
resection of pancreas followed by isolation of healthy islets from the diseased pancreas and
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reinfusion of isolated islets to patient via hepatic portal vein for intrahepatic engraftment
without use of immunosuppressive drugs72,73.
In addition to patients with chronic pancreatitis, islet transplantation is also
proposed for selected patients with other clinical indications: i) brittle T1D with unaware
episodes of hyperglycemic and hypoglycemia; ii) combined organ transplantation (kidney)
in T1D patients with kidney failure; iii) T1D patients under immunosuppressive therapy
for other autoimmune diseases70. Pancreatic islet transplantation along with whole
pancreas transplantation can restore normoglycemia as well as achieve exogenous insulin
independence. However, whole pancreas transplantation is associated with significant
morbidity and mortality at early transplant period. Instead pancreatic islet transplant is
minimally invasive and is carried out by infusion of islets into the liver via portal vein74.
With current advances, pancreatic islet transplantation is equally efficient to whole
pancreas transplantation in normalizing BLG. The excellent therapeutic effect is the
accurate blood glucose level responsive insulin secretion. The success of islet
transplantation was realized after “Edmonton protocol” was established. The protocol uses
glucocorticoid free immunosuppression and the long-term outcome results in 50-70% of
patients achieve insulin independence at 5 years. More than 1500 procedures have been
performed worldwide as of date. However, limited pancreas supply and use of chronic
immunosuppression are the major contributing factors that restricts the applicability of this
procedure75.
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Figure 3: Pancreatic islet transplant procedure and factors contributing to loss of
islets. (Adpated from Anazawa et al. 2019)
Transplantation into the liver via portal vein is the only clinically approved site for
islets. Despite the progress in islet isolation and transplantation procedure, intraportal islet
transplantation suffers from significant loss (50-70%) of functional islet mass during the
peritransplant period76,77, thus requiring islets from more than two donors to stabilize
BGL78. Despite being transplanted from multiple donors, transplanted recipients have βcell function of only 20% of that in healthy individuals79. Multiple factors contribute to this
that include localized hepatic ischemia/reperfusion, low oxygenation rate, endogenous
liver immune response, and instant blood mediated inflammatory reaction (IBMIR).
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Instant blood mediated inflammatory reaction (IBMIR)
IBMIR is a complex non-specific innate immune response generated by contact of
islets to blood when islets are infused to liver via hepatic portal vein. IBMIR is
characterized by rapid activation of coagulation and complement system, rapid activation
of platelets, neutrophils and binding. This generates islet-thrombus and intra-islet
infiltration of dense lymphocyte and macrophage. This cascade of inflammatory reaction
ultimately leads to disrupted islet integrity, morphology and loss of islet mass80,81.
Activation of coagulation cascade and complement includes the initial steps in
IBMIR. Islet isolation step involves treatment of whole pancreas with collagenase and
isolation of “naked islets”. This process exposes molecules (collagen, laminin) that are
thrombogenic in nature. In addition, isolated islets also lack membrane regulators (heparan
sulfate)81,82. Cumulatively, the exposure of naked islets to blood facilitates activation of
coagulation and complement. Further, stress during the procurement procedure, isolation
and culture and brain death of donor induces pro-inflammatory signature with significant
upregulation of tissue factor (TF), monocyte chemoattractant protein-1 (MCP-1), IL-1β
and TNF-α. Strong coagulation cascade peaks as early as 6-12 hrs post transplantation and
associated with upregulated levels of different pro-coagulating factors. Sequentially,
IBMIR is also associated with activation of complement. Deposition of IgG, IgM along
with C1q, C4, C3 and C9 result in formation of pro-inflammatory anaphylatoxins C3a and
C5a80,81,83,84. Activated thrombin promotes the secretion of adhesion molecule (p-selectin),
thus activating platelet aggregation. This results in generation of islet-thrombus.
A panel of cytokines (IL-6, IL-8) recruit neutrophilic granulocytes and
macrophages into the hepatic graft site. Under hypoxic condition, islets express pro18

inflammatory and danger signals like high mobility group box-1 (HMGB-1), IFN-γ, IL-8,
MCP-1. The intraislet macrophages, kuppfer cells, and neutrophils secret IL-1β that
directly impairs insulin secretion and induce islet apoptosis85,86. Moberg et al.87 provides
direct evidence of IBMIR mediated islet loss using in vitro loop assay. Accordingly, rapid
platelets deposition occurs as early as 5 mins reaching maximum by 30 mins. Whereas
CD11b+ neutrophilic granulocytes are predominant cell types infiltrating the islets. The
cells occur as early as 15 mins and peaks by 2 hrs87. Activated neutrophilic granulocytes
generate reactive oxygen derivatives. ROS along with proteases liberated from the granules
of activated granulocytes implement direct damage to the islets84,87,88. In addition, they
secrete MCP-1 to attract macrophages. Macrophages exert killing by phagocytosis, but
simultaneously also act as APCs communicating with lymphocytes in the activation phase
of specific allo-immune responses76.
Strategies to prevent IBMIR
Multiple approaches have been tested to abrogate IBMIR, however all strategies
focus on the coagulation cascade to prevent generation of islet-thrombus. Clinically,
heparin infusion is performed to prevent coagulation. Final islet product is infused in
suspension of transplantation media containing heparin (70 units per Kg of recipient body
weight). Systemic heparin infusion is performed for 48 hrs (3 U/Kg/hr) to prevent IBMIR75.
However, Bennet et al.89 suggested, in ex vivo settings, that even using a high level of
heparin (4 U/ml) was not enough to prevent extensive fibrin deposition and infiltration of
CD11b+ cells. In addition to the risk of systemic bleeding, the relatively short half-life of
systemic heparin impacts the therapeutic potential. Alternatively, Cabric et al.90 used
biotin/avidin strategy to display 40 U of heparin complexes per islet to mitigate IBMIR in
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murine and porcine models. They reported prolonged syngeneic islet graft survival when
300 islets were transplanted under the kidney capsule in a mouse model. However, under
clinical settings islets are transplanted to a patient’s liver via hepatic portal vein. IBMIR is
only observed in intraportal settings where islets come in direct contact with recipient’s
blood circulation. Other anti-coagulation strategies involving low-molecular-weight
dextran sulfate91 and the combination of Tirofiban and activated protein C (APC)92 have
been reported to ameliorate IBMIR in ex vivo models. A study by Contreras et al.93 used a
systemic bolus of recombinant APC to mitigate the early loss of islets. However, the use
of anti-coagulating agents is always linked to high risk of bleeding and hepatic
hematoma94,95. Strategies targeting anti-inflammatory88,96,97 and chemokine inhibitors98
have also been reported to mitigate the effect of IBMIR.

CD47-SIRPα, an innate immune checkpoint
CD47, also known as integrin associated protein (IAP), was identified as missing
protein in Rh-hull red blood cells. The same protein was also isolated with αvβ3 integrin
in leukocytes and placenta99. CD47 is ubiquitously expressed by virtually all cells in the
body. It interacts in cis with integrins, as well as acts as ligand for two members of signal
regulatory protein (SIRP) receptor family100. CD47 is also a receptor for secreted protein
thrombospondin-1 (TSP-1). CD47 is known to modulate immune responses in neutrophils,
macrophages, dendritic cells and T cells101.
CD47 is a member of immunoglobulin (Ig) superfamily with heavily glycosylated
IgV-like extracellular domain at its N-terminus, highly hydrophobic five putative
membrane spanning transmembrane domain, and alternatively spliced C-terminal
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cytoplasmic domain. The extracellular domain is required for functional and physical
interaction with integrins, TSP-1 and SIRP-α99,102. However, functional domain for
enzymatic or protein interaction in the cytoplasmic tail is still at large. Signal regulatory
protein (SIRP) belongs to Ig family of glycoproteins. SIRP family consists of an inhibitory
receptor SIRPα (SHPS1), activating receptor SIRPβ1 and nonsignaling receptor
SIRPγ100,103. SIRPα is widely expressed on myeloid cells, macrophages, dendritic cells and
precursor including hematopoietic stem cells. SIRPα is an inhibitory receptor and interact
with CD47 via three Ig-like extracellular domain. It contains tyrosine based
immunoreceptor tyrosine based inhibitory motif (ITIM) domain in cytoplasmic tail. Upon
ligand binding, the cytoplasmic domain gets phosphorylated and mediates recruitment and
activation of Src-homology domain 2 containing phosphatase SHP-1 and SHP-2 and
ultimately negatively regulates intracellular signaling100,103.
CD47 modulates multiple cell activities including activation of neutrophils and
platelets, transmigration of leukocytes, cell mobility and adhesion, and phagocytosis. The
importance of CD47 in immunoregulation was revealed by the observation that pox virus
upregulate homolog of CD47 as virulence factor to evade host immune responses104,105.
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Figure 4: Multifactorial immunoregulatory role of CD47 (Wiersma, Valerie R., et al.
Atlas of Genetics and Cytogenetics in Oncology and Haematology 2015.)
CD47 delivers “don’t eat me” signal
One of the well-studied aspect of CD47 is “marker of self” or “don’t eat me” signal
delivered to macrophages and dendritic cells via SIRPα100,106-108. Macrophages and
dendritic cells are important regulators of innate and adaptive immune system. They
constantly screen for distinction between self and non-self, such that recognition of
pathogens by pathogen associated molecular patterns (PAMPs) will trigger their activation,
leading to initiation of innate immune response. Interaction of CD47 as “marker of self”
on healthy cells with SIRPα expressed on macrophages and dendritic cells results in
inhibition of phagocytosis, hence coined as “don’t eat me signal”105,109. Evidence of this
phenomenon came from observations that CD47-deficient red blood cells (RBCs) are
efficiently cleared within hours by splenic macrophages, whereas healthy RBCs have long
half-lives in circulation110,111. Also, CD47 is transiently upregulated by hematopoietic stem
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cells upon mobilization or after strong inflammatory signal112. This transient upregulation
is necessary for HSC to avoid being phagocytosed and cleared during their mobilization
from bone marrow to blood. Studies also suggests that leukemic cells upregulate CD47
expression as an effective evasion mechanism. Increased expression of CD47 was
associated with worse overall survival prognosis in patients and contributes to progression
and pathogenesis of the disease due to engagement with SIRPα to inhibit and evade
phagocytosis113.
Studies suggests expression of CD47 on DCs is important for homeostasis and
migration across lymphatics and during inflammatory condition. CD47 is necessary for
maturation of DCs and efficient T cells priming114. CD47-/- murine had selective reduction
of marginal zone CD4+ DCs and blunted immune responses, suggesting the important role
of CD47 in DC maturation and homeostasis. Furthermore, CD47 deficient DCs had
impaired migration to draining lymph nodes, despite the normal expression level of
chemokine receptor115. CD47 has been reported to play a role in activation and
transmigration of neutrophils and platelets. Finley et al.116 showed that blood conduits
modified with recombinant CD47 inhibited activation and adhesion of platelets and
neutrophils. Similar studies suggested CD47-SIRPα signaling can inhibit activation and
mobilization of neutrophils and macrophage in CD47 adhered surfaces117. In addition, the
axis is also important for antibody dependent trogocytosis, a mechanic destruction of target
cell plasma membrane, of cancer cells by neutrophils118.
CD47-SIRPα interaction is highly species and strain specific100 and plays
significant role in graft tolerance119,120. Xenografts activate recipient phagocytes due to the
lack of interaction of donor CD47 with recipient SIRPα. However, xenografts displaying
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recipient CD47 significantly diminishes phagocytic response with survival of grafts119,121.
This is evidenced by significant human hematopoietic engraftment in non-obese diabetic
(NOD)-severe combined immunodeficiency (SCID) mice because NOD-SIRPα shows
enhanced binding to human CD47122.

ProtExTM technology as a facile and effective platform for localized
immunomodulation
Immunomodulation by definition encompasses all therapeutic or preventive
interventions intended to modulate immune responses123. Multiple modalities are
employed to manage immune responses based on disease condition. For instance,
augmentation of immune response is desirable to combat infection, to prevent infection in
states of immune deficiency, as well as to fight cancer. In contrast, in settings of
transplantation, allergy, or autoimmunity strategies to dampen the immune response are
desirable123-125. Multiple drugs or therapeutic agents are often used as single agents or in
combination to modulate the immune system. These agents may interfere with immune
responses at different levels, antigen presentation, T cell activation, proliferation of
regulatory cells, or induction of apoptosis of selective cell types.
In principle, the immunomodulatory biologics are used systemically, i.e., the
infusion into the system by various routes of injection. This schema has significant
drawback as systemically introduced biologics are rapidly cleared from the system.
Alternatively, genes encoding these biologics can be introduce to target cell/tissue as an
attractive platform for the treatment of various inherited and acquired immune disorders126.
However, there are multiple challenges for clinical applicability of gene therapy, including
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safety issues, inefficient delivery of gene of interest, and regulation of target gene
expression126,127. As an alternative approach, our lab has pioneered the ProtExTM
technology that provides a platform to generate functional immunological ligands chimeric
with core streptavidin and their transient and rapid display on biotin-modified biological
surfaces for localized immunomodulation. Another major advantage of the platform is the
ability to simultaneously display multiple immunomodulatory proteins for improved
efficacy.

Figure 5: ProtExTM technology to display multiple immunomodulatory proteins on
the biological or nonbiological surfaces.
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Multiple functional immunomodulatory proteins, including SA-FasL, SA-PDL1,
and SA-4-1BBL, have been generated using this platform and been used to induce localized
tolerance to islet grafts128-130 and cardiac grafts131, efficient engraftment of stem cells132,133
and development of cancer vaccines134,135. Here, in this set of study we extend our
observation as efficient immunomodulatory approach in acute GVHD and IBMIR by
targeting SA-FasL and SA-CD47, respectively.

26

CHAPTER 2
TARGETING FAS-FASL PATHWAY FOR SELECTIVE ELIMINATION OF
ALLOREACTIVE DONOR CELLS FOR PREVENTION OF ACUTE GRAFT
VERSUS HOST DISEASE

Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a well-established
curative treatment modality for multiple high-risk hematologic malignancies as well as
uncurable non-malignant hematological and genetic disorders2,4,51. However, the beneficial
efficacy of this treatment is significantly limited by graft-versus-host disease (GVHD).
GVHD represents a complex disease; while several factors contribute to its pathogenesis,
the major mechanisms underlying the disease are well-elucidated. Interaction of T cell
expressing suitable T cell receptor (TCR) with antigen presenting cells (APCs) that express
recipient allogeneic MHC molecules is the driving force for the development of acute
GVHD. T effector cells activated in response to recipient alloantigens expand and inflict
damage to the recipient tissues. T cells are the main effectors of targeted tissue damage2.
The GVHD causing alloreactive cells constitute a minor subset of total T lymphocytes48,
which presents technical challenge for their complete elimination. Although, rigorous panT cell depletion from the donor graft can significantly reduce the incidence and severity of
acute GVHD, the procedure is associated with multiple complications including failure in
graft engraftment, leukemia relapse, and delayed immune reconstitution47,48,51. Thus, the
major challenge is to control donor immune reconstitution in the recipient post27

transplantation, conserve beneficial donor T cell immune function against leukemia and
infections and reduce the severity of acute GVHD.
One of the distinctive features of the immune system is homeostatic control
involves a phase of contraction after clonal expansion of antigen-activated lymphocytes to
titrate the level back to the base line35,36,136,137. This is achieved by fine tuning between
expansion and death triggered by apoptosis, activation induced cell death (AICD). AICD
is mediated by Fas/FasL (CD95/CD95L) pathway and is an important physiologic strategy
to control the expansion of antigen-activated T cells. AICD requires repeated antigenspecific TCR re-engagement in the presence of IL-2 and does not affect bystander T
cells30,52,136,138. Resting T cells do not express Fas-receptor and express multiple apoptotic
inhibitors (e.g. Flice like inhibitory protein, FLICE, or surviving), whereas activated
antigen-specific T cells upregulate Fas receptor and significantly downregulate antiapoptotic molecules36,52,139. This marked difference makes alloreactive T cells prone to
Fas/FasL mediated apoptosis, while endowing resistant to resting or bystander T cells. In
addition, multiple studies suggest that HSCs133,140-143 and immunosuppressive regulatory T
cells144 are highly resistant to FasL-mediated AICD. The differential response of activated,
naïve, regulatory T cells, and HSC to Fas/FasL-mediated apoptosis provides an attractive
approach to use FasL to selectively eliminate alloreactive T cells without a major negative
impact on HSCs as well as resting T cells that aid in engraftment and T regulatory cells
that modulate alloreactive immune responses.
In our previous studies, we have reported a novel form of FasL protein chimeric
with streptavidin (SA)-FasL that exist as tetramers and oligomers with potent apoptotic
activity on Fas-expressing cells130,145. The protein can be efficiently and rapidly displayed
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on the surface of biotinylated cells and biologics128,130,133,143,145. Most importantly, SAFasL engineered cells or biologics could be employed to eliminate alloreactive T cells for
systemic or localized immunomodulation128,130,131. Since upon activation alloreactive T
cells upregulate Fas expression and become susceptible to FasL-mediated apoptosis, we
hypothesized that the transient display of SA-FasL on donor cells will induce apoptosis in
T cells following activation in response to the recipient alloantigens, thereby blocking acute
GVHD. In line with our expectation, there was significant elimination of donor T cells
upon allogenic stimulation in in vitro as well as in vivo settings. To test our strategy in
mitigating lethal acute GVHD, we employed the haploidentical parent (C57BL/6) to F1
(C57BL/6xBALB/c) setting. We report that recipients that received SA-FasL-engineered
bone marrow cells containing mature T cells were protected from lethal acute GVHD and
survived long term (>100 days), whereas all controls displayed clinical signs of acute
GVHD and met end point by 40 days. The long-term recipients were immunocompetent as
they rejected third party, but not donor, skin grafts. Importantly, this concept also showed
efficacy in a humanized mouse model for xenogeneic GVHD where human PBMC
engineered with SA-FasL was used for transplantation. Thus, this approach has significant
translational potential for the prevention of acute GVHD as a single modality or in
combination with other clinically used approaches.
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Materials and methods
Animals
C57Bl/6 (H2b), BALB/c (H2d), C3H (H2k) and NOD-scid-IL2γRnull (NSG) mice were
purchased from the Jackson Laboratory and breed in our specific pathogen free facility.
C57BL/6.FoxP3hCD2 (hereafter referred as B6.hCD2)146 and B6.SJL-4C.TCR-tg (hereafter
referred as 4C.SJL)147 animals were generously provided by Drs. H. Waldmann of Oxford
University and TV Brennan of Duke University respectively. F1 (C57BL/6 x BALB/c,
H2b/d) were breed in our facility. All animals were maintained in our specific pathogen free
vivarium at the University of Louisville. All experiments were performed in accordance to
approved protocols by Institutional Animal and Use Committee, University of Louisville.

Modification of cell surface to engineer with SA-FasL protein
Spleens from C57BL/6 or 4C.SJL were harvested and processed into single-cell suspension
using frosted slides. Red blood cells were lysed using a home-made buffered ammonium
chloride solution. SA-FasL engineering of spleen cells was done following previously
reported protocols145. In brief, cells were incubated in 5 µM EZ-LinkTM Sulfo-NHS-LC
biotin (hereafter referred to as biotin) solution (ThermoFisher Scientific, Ref# 21335) in
sterile PBS at room temperature for 30 min. After washing with PBS, cells were incubated
in PBS containing indicated amount of SA- or SA-FasL protein for 30 min in a cold room
by constant rocking. Cells were washed before further experimental use.
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MLR cultures and proliferation assay
Standard mixed lymphocyte culture assay was performed128,130 where spleen cells from
4C.SJL was used as responders against 2000 cGy irradiated BALB/c spleen cells. Briefly,
SA/SA-FasL engineered at indicated levels or unengineered 4C.SJL spleen cells were
incubated at 37 °C for 45 mins to collect pan-T cells. Non-adherent pan-T cells were
collected, washed and co-culture with irradiated BALB/c spleen cells (105 cells each/well)
in 96 well U-bottom plate in complete MLR medium128. For [3H]thymidine incorporation
assay, the cultures were pulsed with [3H]thymidine (1μCi/well) for last 16 hrs before
harvest. Cultures were then harvested with Tomtec cell harvester and analyzed in a beta
plate counter to assess DNA-associated radioactivity as measure of proliferation [counts
per minute (cpm)]. For flowcytometric analysis, the cells were harvested, and surface
stained as described below.
For in vitro apoptosis assay, spleen cells from 4C.SJL mice were engineered with
SA-FasL (100 ng). SA-FasL engineered or unmodified 4C.SJL spleen cells were
fluorescently labelled with 2.5 μM carboxyfluorescein succinimidyl ester (CFSE;
ThermoFisher Scientific Ref# C34554) or 2.5 μM Cell trace violet (CTV; ThermoFisher
Scientific Ref# C34557), respectively, following manufacturer’s instruction. Fluorescently
labelled 4C.SJL pan-T cells were mixed together in equal ratio to generate 4Cmix (1:1)
cell suspension. Irradiated BALB/c spleen cells were cultured with 4Cmix cells at different
indicated ratio in complete MLR medium. At indicated time points cells were harvested
and analyzed for H2Kd- cells by flow cytometry.
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In vivo monitoring of adoptively transferred cells
Spleen cells from 4C.SJL or B6.hCD2 animals were harvested and engineered with SAFasL or SA (control) proteins at indicated levels. Engineered cells were fluorescently
labelled with 2.5 μM cell trace violet (CTV). Each F1 recipient was intravenously injected
with 5x106 CTV labelled SA- or SA-FasL-engineered 4C.SJL cells or 10x106 SA/SAFasL-engineered B6.hCD2 spleen cells. Animals that received 4C.SJL or B6.hCD2 spleen
cells were euthanized 48 or 72 hrs post transplantation and spleen cells were analyzed by
flow cytometry for donor cells.

Collection of human PBMC
Human Peripheral blood mono-nuclear cells (PBMCs) were isolated as reported before148
from healthy donors under signed informed consent approved from Institutional review
board of University of Louisville. Peripheral blood was collected in heparin containing
vacutainer (BD Bioscience, Ref# 364606). PBMCs were purified and collected from buffy
coats by Ficoll-paque (GE, Ref# 17-1440-03) density centrifugation and washed by sterile
PBS before further use. Engineering of human PBMCs was done as described before145.

Induction of acute GVHD in the parent-to-F1 setting
A clinically relevant haploidentical setting was used to assess lethal acute GVHD as
described before with some modifications39. Female or Male F1 (H2b/d) recipients, 10-12
weeks old, were lethally irradiated with single dose of 1000 cGy (Gammacell 40 Exactor,
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137

Cs source) and 4 hrs later transplanted with 10x106 whole bone marrow cells and 20x106

whole spleen cells from female or male C57BL/6 (H2b) mice. For engineering the graft
inoculum, only whole spleen cells were engineered with SA-FasL as described above.
Animals were followed twice a week for acute GVHD scoring, including five clinical
parameters as explained before149,150. Each parameter received score of 0 (minimum) to 2
(maximum). A clinical GVHD score index was generated by summation of the five criteria
score (maximum value=10). Animals that reached total score of > 6 and lost body weight
>25% was considered as at the end point. All animals were supported with soaked food
throughout the study.

Skin transplantation
Skin grafts were procured from tail of euthanized BALB/c (H2Kd) donor or C3H (H2Kk)
third party mice. Each section of tail skin graft from each donor was transplanted onto
prepared skin bed site of an isoflurane anesthetized long term animal. The site was covered
with an adhesive bandage, which was removed after 7 days. Animals were followed post
transplantation and followed until complete loss of skin grafts151.

Xenogeneic GVHD protocol
Humanized xenogeneic GVHD was induced as described before148. Briefly, 8-10 weeks
old NSG females received sublethal dose (200 cGy) of total body irradiation and injected
4 hrs later with 10x106 engineered or unmodified human PBMCs via tail vein. Fresh human
PBMCs were used in all experiments. Animals were followed for body weight twice a
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week and the development of xenogeneic GVHD was assessed by five parameters: loss in
body weight, posture, mobility, fur texture and skin texture152. Each parameter received a
score of 0 (minimum) to 2 (maximum). Animals that reached significant body weight loss
(> 25%) and total GVHD score > 6 were considered to reach end point and euthanized.

Antibodies and Flow cytometry
Fluorochrome conjugated monoclonal antibodies (Table 1 and 2) were titrated for optimal
concentration before use. For cell surface staining, cells were incubated with the respective
antibodies for 30 mins at 4 °C. For intracellular cytokine staining, cells were stimulated
with PMA (50 ng/ml) and Ionomycin (1 μg/ml) for 6 hrs in presence of Golgi plug (BD
Biosciences, Ref# 51-2301KZ) for last 4 hrs. After incubation, cells were surface stained
followed by fixation (eBiosciences, Ref# 00-5123-43) and permeabilization (eBiosciences,
Ref# 00-8333-56). For intracellular staining, cells were incubated with respective cytokine
antibodies for 1 hr at room temperature. For intranuclear FoxP3 staining, Fix/Perm buffer
(eBiosciences, Ref# 00-5523-00) was used per manufacturer’s instructions and staining
with anti-FoxP3 antibody for 30 min at 4 °C. Flow cytometric analysis was done by using
LSR II with FACS Diva software. Data analysis was done by using FlowJo software
(Treestar).
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Table1. Phenotypic analysis of mouse cells by flow cytometry
Marker
CD3
CD4
CD8
CD44
CD62L
PD1
CTLA4
CD25
FoxP3
CD45
Fc block

Clone
500A2
RM4-5
53-6.7
IM7
MEL-14
RMP1-30
UC10-44B9
PC61.5
FJK-16s
30-F11
93

Vendor
BD Biosciences
BD Biosciences
BD Biosciences
eBiosciences
BD Biosciences
eBiosciences
eBiosciences
eBiosciences
eBiosciences
eBiosciences
Biolegend

Cat#
560771
557956
557654
48-0441-82
563252
48-9981-82
12-1522-83
25-0251-82
53-5773-82
45-0451-80
101320

Table 2. Phenotypic analysis of human cells by flow cytometry

Marker
CD45
CD3
CD4
CD8
CD25
CD45RO
CD197
CD95
CD127
CD20
CD4
CD20
CD16
CD3
CD8
CD4

Clone
HI30
UCHT1
L200
SK1
M-A251
UCHL1
150503
DX2
HIL-7R-M21
2H7
SK3
2H7
3G8
UCHT1
RPA-T8
RPA-T4

Vendor
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
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Cat#
564047
563109
560836
561423
557741
563749
562555
556640
558598
560735
566320
563779
562874
560835
555369
555347

Cells isolation and CD25 depletion
Single cells suspension from spleens were depleted of CD25+ cells using Miltenyi Biotec
kit following manufacturer’s instructions. Cells were sequentially stained with anti-CD25
PE antibody (BD Biosciences, Ref#553866) and super-paramagnetic microbeads
conjugated with monoclonal anti-PE antibodies (Miltenyi Biotec, Ref# 130-048-801).
After staining, cells were passed through LS columns (Miltenyi Biotec, Ref# 130-042-401)
and eluted cells were collected as CD25- cell fraction. CD25- cell fraction was then washed
with PBS and followed for SA-FasL engineering as described above.
RNA isolation and quantitative RT-PCR
Total RNA was extracted from liver, colon and small intestine tissues using Trizol reagent
(Life Technologies, Ref# 15596018) according to manufacturer’s instruction. Total RNA
was quantified using NanoDrop ND-2000c spectrophotometer (ThermoFisher Scientific)
and cDNA was reverse transcribed from 4 μg of the total RNA using SuperScriptTM IV
VILOTM Master Mix (ThermoFisher Scientific, Ref# 11756050) following manufacturer’s
instruction. Quantitative RT-PCR was performed for different genes (Table 3) using
TaqMan probe assay on Quant Studio 3 RT-PCR system (Applied Biosystems). Each PCR
reaction consisted of 5 μl of TaqMan Fast Advanced master mix, 1 μl of TaqMan primer
and FAM/VIC labelled MGB probes, 1 μl of cDNA sample (from 1:10 dilution), and 3 μl
of nuclease-free water in a final volume of 10 μl. The thermal cycling conditions were as
follows: 1 cycle of 95 °C for 20s, followed by 40 cycles of 95 °C for 1s and 60 °C for 20s.
Transcript expression was normalized to GAPDH housekeeping gene and represented as
fold change (2-ΔΔCt, ΔΔCt = ΔCtexperimental - ΔCtcontrol).
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Table 3. TaqMan assay for indicated gene expression in tissues
Taqman Primer
CCl2/ MCP1
IL-1β
FoxP3
GATA3
TNF-α
IFN-γ
IL-4
IL-6
IL-10
Rorc/ ROR-γT
TGF-β1
Tbx21/ T-Bet
GAPDH
IL-12b/ IL-12 p40
IL-23α

Assay ID
(Thermofisher)
Mm00441242_m1
Mm00434228_m1
Mm00475162_m1
Mm00484683_m1
Mm99999068_m1
Mm01168134_m1
Mm00445259_m1
Mm00446190_m1
Mm01288386_m1
Mm01261022_m1
Mm01178820_m1
Mm00450960_m1
Mm99999915_g1
Mm01288989_m1
Mm00518984_m1

Histopathology
Tissues from animals on day 21 after HSCT were harvested, fixed in 10% neutral buffered
formalin (Leica, Ref# 3800602) and embedded in paraffin. Sections (5 μm) were cut with
microtome and subsequently stained with hematoxylin and eosin.
Statistics
Statistical analysis was performed using GraphPad prism software v.8 (Graphpad prism,
CA). Comparison of the survival curves was done using log-rank (Mantel-Cox) test. Data
are shown as individual data points or as mean ± SEM as depicted in the figure legends.
Comparison of the means was performed using unpaired, two tailed test or Man-Whitney
t-test as indicated. For multiple comparison, one-way ANOVA with tukey posttest was
done. Statistical significance was defined as p < 0.05.
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Results
T effector cells engineered with SA-FasL are efficiently eliminated in response to
alloantigens
Alloreactive T cells upregulate Fas receptor as early as 1-2 days post allo-mixed
lymphocyte reaction (MLR) assay rendering them sensitive to FasL by day 251. To test if
SA-FasL engineered alloreactive cells will have reduced proliferation upon allogeneic
stimulation, we performed [3H]thymidine incorporation assay. Spleen cells from 4C mice,
TCR-transgenic on C56BL/6.SJL (CD45.1) background, were used as responders to
irradiated BALB/c spleen cells. The T cells in 4C has selective reactivity against BALB/c
H2-I-Ad alloantigen, which is widely expressed in mouse tissues147. Spleen cells from 4C
were engineered with SA-FasL (SA-FasL-4C) at different levels or with control protein
SA (SA-4C). SA-FasL-4C cells or SA-4C cells or unmodified (4C) cells were co-cultured
with irradiated BALB/c cells. There was robust proliferation of 4C or SA-4C cells by 48
and 72 hours post culture observed by significant incorporation of [3H]thymidine. In
contrast, we observed significant inhibition of proliferation of SA-FasL-4C cells at all
protein concentrations tested (Fig. 6A). This demonstrate that SA-FasL on the surface of
alloreactive T cells is extremely effective, even at the lowest protein concentration tested,
in blocking their proliferation in an in vitro allo-MLR setting.
To provide evidence that SA-FasL targets both CD4+ and CD8+ T cells for
inhibition, we assessed the frequency of these cells using Abs to CD4, CD8, and Vβ13
TCR specific for the target alloantigen in flow cytometry. There was significant reduction
in frequency of alloreactive CD4+ and CD8+ T cells expressing TCR Vβ13 in the SA-FasL
engineered group as compared with controls (Fig. 6B).
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SA-FasL on the surface can induce apoptosis in activated alloreactive T effector
cells in three different ways; i) autocrine where SA-FasL engages Fas on the same T cell,
ii) paracrine where SA-FasL on a T cell engages Fas on another T cell, or iii) combination
of autocrine and paracrine. To investigate the relative contribution of these death pathways
we performed co-culture MLR studies. SA-FasL engineered 4C and unmanipulated 4C
cells were labelled with CFSE and CTV, respectively. Fluorescence labelled 4C cells were
then mixed at 1:1 ratio and used as responders at indicated ratios with a fixed number of
irradiated BALB/c cells as stimulators. Unmanipulated 4C cells underwent robust
proliferation by 72 hrs with distinct daughter cell generations. In marked contrast, there
was minimal daughter cell generation in SA-FasL-4C cells at all cell ratios used (Fig. 6C),
suggesting that SA-FasL-4C cells were primarily being eliminated by autocrine apoptosis.
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Figure 6. SA-FasL transiently displayed on the surface of T cells is effective in
blocking their proliferation in response to alloantigens in vitro. (A) In vitro
proliferation assay. SA-FasL-engineered or unmodified 4C T cells were stimulated with
irradiated BALB/c splenocytes for 48 or 72 hrs. Cultures were pulsed with [3H]thymidine
for the last 16 hrs of incubation and harvested using a beta plate counter. Cell associated
radioactivity was measured using a scintillation counter. Data were pooled from two
independent experiments. (B) Frequencies of live CD4, CD8, and Vβ13 T cell
subpopulations in mixed lymphocyte cultures. Experimental conditions are the same as in
(A), except instead of pulsing with [3H]thymidine, cultures were harvested at 72 hrs,
stained with the Abs to indicated markers and analyzed using flow cytometry. Data were
pooled from two independent experiments. (C) SA-FasL induces autocrine death in
alloreactive T cells. CTV labelled unmodified 4C cells were mixed one-to-one ratio with
CFSE labelled SA-FasL-4C cells and used as responders at the indicated ratios against a
fixed number of irradiated BALB/c cells as stimulators. Cells were harvested after 72 hrs
of incubation and analyzed for live cells using flow cytometry. Representative flow dot
plots of proliferating 4C cells. Date sets pooled from two independent experiments. Oneway ANOVA with Tukey multiple comparison was used in (A) and (B). Unpaired two
tailed t-test was used in (C). Data are shown as mean ± SEM. cpm counts per minute. **p
< 0.01, ***p < 0.001, ****p <0.0001
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To recapitulate in vitro findings in an in vivo model, we used 4C.SJL (CD45.1)
transfer to F1 transgenic recipients where 4C cells are expected to respond to the recipient
H2-I-Ad antigen. 4C.SJL spleen cells were modified with biotin followed by engineering
with SA-FasL (100 ng/106 cells) or SA (50 ng/106 cells) as the control protein. Each F1
animal was adoptively transferred with 5x106 CTV labelled SA-FasL-4C or SA-4C cells.
After 48 hrs of transfer, spleen from F1 recipients were harvested and analyzed for CD45.1+
donor cells by flow cytometry. F1 recipients that were transferred with SA-FasL-4C cells
had significantly less frequency and absolute numbers of live total donor cells (7AADCD45.1+) and CD45.1+CD4+ T cells (Fig. 7A and 8A). SA-FasL-4C recipients had 3.8fold reduction in live donor cells and 5.7-fold reduction in live CD4+ donor cells as
compared with SA-4C recipients. In addition, substantially less proliferated donor cells
(CTVlow CD45.1+) were observed in SA-FasL-4C as compared with SA-4C recipients (Fig.
7A and 8A). This was evident by distinct daughter cell generations in SA-4C, but not in
SA-FasL-4C, group (Fig. 8B). Annexin V staining revealed more apoptotic cells in SAFasL-4C as compared with SA-4C recipients (Fig. 7A), providing in vivo evidence for
alloreactive T cells undergoing apoptosis.
To further corroborate our in vivo observation, we performed this in vivo tracking
study using a non-TCR transgenic model using spleen cells from C57B/6.hCD2 (H-2Kb)
donors. These mice are transgenic for human CD2 expressed under the FoxP3 promotor of
mice, providing a convenient means of tracking Treg cells using an Ab to human CD2146.
Cells were engineered at indicated doses of SA-FasL or SA proteins, labelled with CTV,
and 10x106 cells were injected intravenously into F1 (H2Kb/d) recipients. Animals were
euthanized at 72 hrs and splenocytes were subjected to flow analysis. There was
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significantly reduced frequency (Fig. 7B) as well as absolute number (Fig. 8C) of live
donor total (H2Kd- CTV+) cells, CD4+ and CD8+ T cells as well as proliferating (H2KdCTVlow) donor T cells (Fig. 7B and 8C) at 72 hrs post transfer in F1 recipients of SA-FasL
engineered cells as compared with those that received SA engineered cells. Interestingly,
there was also a significant drop in the frequency and absolute numbers of T regulatory
cells (hCD2+) in SA-FasL-spleen recipients (Fig. 7B and 8C). Importantly, these effects
were observed for almost all SA-FasL protein doses tested, demonstrating the apoptotic
efficacy of SA-FasL plausibly due to its autocrine mode of action.
Taken together, these findings demonstrate that the transient display of SA-FasL
protein on T cells is an efficient strategy of purging out pathogenic alloreactive cells with
great potential to mitigate acute GVHD.
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Figure 7. Elimination of alloreactive cells by SA-FasL engineering in an allogeneic
adoptive transfer model. (A) Tracking frequency, proliferation, and apoptosis of 4C cells
in F1 recipients. 4C.SJL cells were labelled with CTV and engineered with SA or SAFasL proteins and adoptively transferred into F1 recipients (5x106 cells/mouse). After 48
hrs post-transplant, spleen cells of recipients were analyzed for frequency of donor total
live (7AAD- CD45.1+) cells, CD4+ T (CD45.1+CD4+) cells, proliferating (CTVlow) cells,
and apoptotic (CD45.1+AnnexinV+) cells. Data pooled from two independent experiment,
with n=3-4/group. (B) Tracking B6.hCD2 donor cells in F1 recipients. B6.hCD2
splenocytes were labelled with CTV and engineered with SA (50 ng/106 cells) or the
indicated amounts of SA-FasL protein. Cells were adoptively transferred into F1 recipients
(10x106 cells/mouse) that were euthanized 72 hrs later to harvest the spleen. Splenocytes
were analyzed in flow cytometry by gating on donor cells (H-2Kd-) for the frequency of
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total cells (CTV+H-2Kd-), CD4+ (CTV+H-2Kd-CD4+), CD8+(CTV+H-2Kd-CD8+) , and Treg
(CTV+H-2Kd-CD4+hCD2+) cells as well as proliferating donor cells (CTVlowH-2Kd-). Data
pooled from three independent experiments with n=3-4/group. For comparison of mean,
Mann Whitney test was used in (A), One-way ANOVA with Tukey post test was used in
(B). Data represented as mean ± SEM. *p <0.05**p < 0.01, ***p < 0.001, ****p <0.0001
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Figure 8. SA-FasL engineered alloreactive cells are eliminated in in vivo model (A)
Absolute number of 4C cells shown in Fig. 8A. Data pooled from two independent
experiments. (B) Representative flow plot showing 4C cell proliferation, equal number of
live events were acquired. (C) Absolute number of B6.hCD2 donor cells subpopulations
shown in Fig. 8B. Data pooled from three independent experiments with n=3-4/group. For
comparison of mean, Mann Whitney test was used in (A), One way ANOVA with Tukey
post test was used in (C). Data represented as mean ± SEM. *p <0.05, **p < 0.01, ***p <
0.001, ****p <0.0001
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Transient display of SA-FasL on donor T cells Engineering of donor graft to display
SA-FasL efficiently prevents lethal acute GVHD
Selective depletion of alloreactive donor cells from graft is an efficient strategy for
prevention of lethal acute GVHD2,153. Given the significant depletion of alloreactive T cells
by engineering of cells to display SA-FasL on their surface, we assessed the efficacy of
this strategy to prevent lethal acute GVHD. We used haploidentical parent (C57BL/6,
H2Kb) to F1 (C57BL/6xBALB/c, H2Kb/d) model, simulating the broad use of
haploidentical bone marrow cells in the clinic. Recipient F1 animals were lethally
irradiated at 1000 cGy and 4 hrs later were infused with 20x106 SA-FasL engineered or
unmodified spleen cells mixed with 10x106 unmodified whole bone marrow cells. Controls
that received only bone marrow cells survived long-term without any signs of GVHD as
expected. However, recipients of a mixture of bone marrow cells and unmodified T cells
developed acute GVHD symptoms, including bodyweight loss, hunching, and diarrhea,
and expired with a median survival time of 26 days (Fig. 9A). The survival of recipients
transplanted with SA-engineered donor spleen cells (SA group) and the severity of GVHD
were not significantly different from the control group (MST = 25 days; Fig. 9A). The
efficacy of SA-FasL was dose dependent as animals receiving T cells engineered with 25
ng SA-FasL per 106 cells showed better survival at > 100 days than recipients transplanted
with cells engineered with 10 or 5 ng protein (⁓73%, ⁓63%, and 20%, respectively, Fig.
9A). Clinical GVHD scores for these groups correlated with the survival rates. Taken
together, these results demonstrate the efficacy of this engineering platform with SA-FasL
in preventing acute GVHD in a clinically relevant model.
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We next analyzed long-term animals for immune composition. Long term animals
(>100 days) that received SA-FasL engineered grafts had full donor chimerism (Fig. 10).
Immune cells in spleen, peripheral blood and bone marrow were donor derived (H-2Kb+,
Kd-), suggesting efficient engraftment of donor stem cells. Importantly, the frequency and
absolute number of immune cells, including Treg cells (CD4+CD25+FoxP3+), T effector
cells (CD4+CD44hiCD62L-), NK cells (NK1.1+CD3-) as well as ratios between Treg and
Teff cells in the spleen of long term animals were comparable to the BM control group that
did not receive splenocytes (Fig. 9B and 11A). Similar observations were also made with
peripheral blood lymphocytes (Fig. 11B). These results demonstrate that long term animals
have efficient overall lymphoid reconstitution.
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Figure 9. Engineering donor graft with SA-FasL abrogates lethal acute GVHD and
show efficient lymphoid reconstitution. (A) Survival of F1 recipients transplanted with
a mixture of allogeneic bone marrow and splenocytes. Lethally irradiated F1 animals were
transplanted with C57BL/6 bone marrow cells (20x106) co-mixed with syngeneic spleen
cells (10x106) engineered with SA (12.5 ng/106 cells) or the indicated amount of SA-FasL.
Animals transplanted with bone marrow only (BM) or a mixture of unmodified splenocytes
and bone marrow cells (Spleen) served as controls. Animals were followed for body
weight, clinical GVHD scores and survival. (B) Frequency of CD4+ Treg cells, Tem and
NK cells in long term (>100 days) animals compared with bone marrow only recipients
and unmanipulated naïve F1 animals. For comparison of survival curves log-rank (Mantel48

cox) test was used in (A). For comparison of means in (B), one-way ANOVA with Tukey
posttest was used. Data represented as mean ± SEM. *p <0.05**p < 0.01, ***p < 0.001,
****p <0.0001

Figure 10. Long term SA-FasL-spleen recipients show full donor chimerism. Long
term animals (>100 days) were analyzed for donor chimerism (H2Kb vs H2Kd) in bone
marrow, peripheral blood and spleen. Frequency of H2Kd- (donor cells) in each cell
compartment was analyzed by flow cytometry. Data shown as mean ± SEM. Mann
Whitney test was used for mean comparison. *p <0.05, **p <0.01

49

Figure 11. Immunophenotyping analysis of long-term animals. Absolute number in
spleen (A) and frequency in peripheral blood (B) of long-term recipients (>100 days) of
SA-FasL-spleen cells compared with long-term recipients of bone marrow cells without
GVHD causing spleen cells and naïve unmanipulated F1 animals. Data represented as
mean ± SEM. One way ANOVA with Tukey posttest was used for statistical analysis.
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Long term SA-FasL-engineered donor cell recipients are functionally immune
competent.
One of the important aspects in HSCT recipients is the immune competency. The
recipients should be competent enough to initiate immune responses against third party
antigens, to ward off infections, while maintaining tolerance to allo-antigens. To assess the
functional immunity in long term SA-FasL-engineered grafts recipients (>90 days), we
tested their ability to reject third party allografts. Two heterotopic skin grafts were applied
to trunk of each mouse from TBI + BM group or SA-FasL-group (10 ng). One from
BALB/c (H2Kd), which is targeting alloantigen in GVHD settings, and one from C3H/HeJ
third party (H2KK) donors (Fig. 12). Interestingly, all long-term animals transplanted with
BALB/c skin grafts accepted the graft, indicating the presence of systemic tolerance against
recipient alloantigens (Fig. 12A and B). In marked contrast, all third party C3H/HeJ skin
grafts were rejected in both groups (Fig. 12A) with median survival of 22 days. These
results suggest that, at this time after transplantation, T cell immune reconstitution was
competent to enable rejection response against third party skin grafts, while maintaining
tolerance to recipient allogenic antigens.
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Figure 12. Long term SA-FasL-spleen recipients are immune competent. Long term
animals that received bone marrow cells only without GVHD causing spleen cells and
bone marrow cells along with SA-FasL-spleen cells were challenged with simultaneous
donor (BALB/c, H2b) and third party (C3H, H2k) skin grafts. Animals were followed for
complete graft rejection and noted as day of graft survival. (A) Skin allograft survival.
(B) Representative pictures of skin grafts on day 7 and 35 post-transplantation. For
comparison of survival curve log-rank (Mantel-cox) test was used. ***p < 0.001, ****p
<0.0001
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SA-FasL recipients exhibit reduced activated alloreactive Th1 phenotype.
Although our data provide direct evidence that physical elimination of alloreactive
T cells is an important mechanism of the observed prevention of GVHD in our model,
apoptosis initiate by SA-FasL may set in motion other immunoregulatory mechanisms that
may accentuate the efficacy of SA-FasL in our model. Thus we analyzed liver, mesenteric
lymph nodes (mLN) by flow cytometry and target organs (colon, ileum and liver) by qRTPCR during the efferent phase of acute GVHD, day 21, the time point when control group
animals that received unmodified spleen cells had significant loss in body weight.
Activated CD4+ T cells (CD4+FoxP3-CD44+CD62L-PD1+) and CD8+ T cells (CD8+CD25+
and CD8+CD44+CD62L-PD1+) were significantly higher in frequency in mLN and liver in
the control group as compared with the SA-FasL group (Fig. 13A). Similar level of
significance was also observed when analyzed as absolute numbers per gram in liver, but
not in mLN (Fig. 14B). Interestingly, recipients of unmodified spleen cells had
substantially higher frequency and absolute numbers of Treg cells (CD4+CD25+FoxP3+)
than SA-FasL-spleen recipients in the liver and frequency, but not absolute cell numbers,
in mLN (Fig. 13A and 14B). However, the Treg (CD4+CD25+FoxP3+) and activated T
effector (CD4+FoxP3-CD44+CD62L-PD1+ or CD8+CD44+CD62L-PD1+) cell ratio was not
significant between the control and SA-FasL groups in the tissues analyzed (Fig. 13B).
These observations suggest that the primary mechanism that SA-FasL prevents acute
GVHD is physical elimination of alloreactive T effector cells, resulting in reduced
frequency and absolute numbers in the target tissues.
qRT-PCR analysis of GVHD target tissues (liver, colon and small intestine) from
control group that received unmodified spleen cells had significantly higher expression
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profile of inflammatory cytokines (IFN-γ, TNF-α, and IL-6), all are known mediators of
acute GVHD154, as compared with SA-FasL-spleen recipients (Fig. 13C). In addition,
GVHD control group also had higher level of T-bet transcription factor, a master regulator
of Th1 differentiation155, than SA-FasL-spleen recipients in all GVHD target organs (Fig.
13C). Interestingly, upregulated Th1 response in GVHD control group was associated with
augmented expression level of IL-4, mediator of Th2 differentiation, in liver (p = 0.0084)
and colon (p = 0.0205) of SA-FasL-spleen recipients as compared with GVHD control
group without an apparent difference in small intestine (Fig. 13C). Similarly, the levels of
GATA3, a master regulator of Th2 differentiation156, transcript was significantly higher
(p <0.0001) in large intestine, but not the liver or small intestine, of SA-FasL-spleen
recipients than GVHD controls (Fig. 15). GVHD control group also had higher level of
other inflammatory mediators, including IL-1β (p = 0.0111), but the level of IL23p40 did
not reach statistical significance (p=0.1006) in the liver (Fig. 15). We observed a similar
pattern in the large intestine, but in the small intestine SA-FasL-spleen recipients had
significantly higher expression level of IL23p40 (p = 0.0001; Fig. 15). SA-FasL-spleen
recipients had significantly less transcripts of chemokine CCL2 in liver (p = 0.0099) and
in small intestine (p = 0.0172; Fig. 13). Interestingly, SA-FasL-spleen recipients had
significantly higher expression level of RORγt in the liver (p= 0.0003) and small intestine
(p= 0.0004), but significantly lower expression in large intestine (p <0.0001; Fig. 15). In
marked contrast, when analyzed for FoxP3, transcription factor for Treg cells, GVHD
control animals had higher level than SA-FasL-spleen recipients (Fig. 15).
The qRT-PCR data was further corroborated by intracellular cytokine assay using
spleen cells stimulated with phorbol myristate acetate (PMA) and ionomycin. SA-FasL-
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spleen cells recipient had significantly lower frequency, but not absolute numbers, of CD4+
cells secreting IFN-γ (p=0.0175) and TNF-α (p=0.0125) (Fig. 16). We did not observe any
difference between the groups for IFN-γ or TNF-α or granzyme B producing CD8+ T cells
(Fig. 16). Histologically, there was evidence of villous blunting (colon and ileum),
intrahepatic infiltration and bile duct epithelial infiltration in the liver of GVHD control
groups when compared with SA-FasL-spleen and BM recipients (Fig. 17). Taken together,
these data suggest that SA-FasL-spleen recipients are protected from lethal acute GVHD
by elimination of alloreactive T cells resulting in significantly reduced activated
alloreactive T cells in the target organs by day 21. This was further supported by
significantly higher transcripts of proinflammatory cytokines, Th1 skewed T cell
phenotype, and other inflammatory mediators in GVHD control animals that received
unmodified spleen cells but not SA-FasL-spleen recipients.
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Figure 13. SA-FasL-spleen recipients have less activated cells and inflammatory
mediators of acute GVHD at day 21 post transplantation. (A) Frequency of activated
cells and regulatory T cells in mesenteric lymph nodes (mLN) and the liver. Intrahepatic
immune cells and mesenteric lymph nodes were analyzed for activated CD4 (CD4+FoxP3CD44+CD62L-PD1+) and CD8+ T cells (CD8+CD25+; CD8+CD44+CD62L-PD1+) and Treg
cells (CD4+CD25+FoxP3+). (B) Ratio of Treg cells to activated CD4+ and CD8+ T cells.
(C) qRT-PCR analysis on target tissues [liver, large intestine (LI) and small intestine (SI)]
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at day 21 post transplantation. Total RNA from liver, colon and ileum was isolated and
subjected to TaqMan based qRT-PCR assay for indicated cytokines, transcription factors,
and chemokines. Fold change expression (2-ΔΔCt) was calculated with respect to GAPDH
as house-keeping gene and bone marrow only recipients. Data representative of two
independent experiments and shown as mean ± SEM. For comparisons, One way ANOVA
with Tukey posttest was used in (A), (B) and (C). *p <0.05**p < 0.01, ***p < 0.001, ****p
<0.0001
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Figure 14. Immunophenotyping of recipients at day 21 post transplantation.
Mesenteric lymph nodes (mLN) and liver infiltrating cells were analyzed at day 21 posttransplantation. (A) Frequency of CD4+ activated T cells (CD4+CD25+FoxP3-). (B)
Absolute number of CD4+ and CD8+ activated T cells and Treg cells in mLN and liver.
Data pooled from two independent experiments and shown as mean ± SEM. For
comparison, One way ANOVA with Tukey posttest was used in (A) and (B). *p
<0.05**p < 0.01, ***p < 0.001, ****p <0.0001
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Figure 15. qRT-PCR analysis of GVHD target organs for immune markers. Total
RNA from liver, colon, and ileum was isolated and subjected to TaqMan based qRT-PCR
for the expression profile of multiple immune genes as indicated. Fold expression (2-ΔΔCt)
was calculated with respect to GAPDH, as a house keeping gene, and bone marrow only
recipients. Data represented as mean ± SEM. One way ANOVA with Tukey posttest was
used for statistical comparison. *p <0.05**p < 0.01, ***p < 0.001, ****p <0.0001
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Figure 16. Intracellular cytokine analysis on spleen cells. Frequency and absolute
number of CD4+ and CD8+ T cells expressing IFN-γ, TNF-α, and granzyme B. After 21
days post transplantation, spleen cells were harvested from the indicated groups, stimulated
with PMA and ionomycin, and analyzed using flow cytometry. Data are from cells pooled
from multiple animals and represent two independent experiments. Data are represented as
mean ± SEM. One way ANOVA with Tukey posttest was used for statistical comparison.
*p <0.05**p < 0.01, ***p < 0.001, ****p <0.0001
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Figure 17. Representative H&E staining of GVHD target organs from each cohort.
GVHD tissues were harvested at day 21 post transplantation, formalin fixed, and paraffin
embedded. H&E staining was performed on tissue section for the indicated groups.
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Donor CD25+ Treg cells are indispensable for the prevention of acute GVHD.
CD4+ CD25+ regulatory T cells can suppress expansion of alloreactive T cells and
inhibit lethal acute GVHD157,158. However, massive infusion of Treg cells at 1:1 ratio with
T effector cells (CD25-) is required for protection53,158. To assess the contribution of Treg
cells for the protection against acute GVHD in our model, we depleted CD25+ T regulatory
cell population from donor cell inoculum (Fig. 18) and then used the Treg-deplete
splenocytes for adoptive transfer into lethally irradiated F1 recipients. Recipients
transplanted with whole unmodified splenocytes developed fatal signs of acute GVHD with
median survival time of 34 days. Whereas, animals receiving whole SA-FasL engineered
splenocytes were protected from lethal GVHD with 80% of animals survived long term (>
60 days). Surprisingly, all F1 recipients of Treg-deplete splenocytes engineered with SAFasL developed signs of acute GVHD with severe diarrhea, hunched posture and decreased
motion, and expired with a median survival time of 28 days as compared with 34 days for
GVHD controls (Fig. 19; p=0.043). Taken together, these results demonstrate the critical
role of donor Treg cells in the prevention of acute GVHD in our model.
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Figure 18. Depletion of CD25+ cells from donor inoculum. (A) Representative flow
dot plot for CD25+ and FoxP3+ CD25+ cells in SA-FasL-spleen and CD25 depleted SAFasL-spleen inoculum, indicating significant depletion of CD25+ cells. (B) SA-FasL
engineering level on CD25+ cells depleted inoculum. Histogram plot suggesting similar
level of SA-FasL engineering on CD25+ replete inoculum and CD25+ deplete inoculum.
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Figure 19. CD25+ cells are indispensable for observed protective effect of SA-FasL
for acute GVHD. Lethally irradiated F1 mice received bone marrow cells admixed with
unmodified or SA-FasL engineered spleen cells or SA-FasL engineered CD25-deplete
spleen cells. Animals were monitored for signs of acute GVHD and survival. For
survival curve comparison, log-rank (Mantel-Cox) test was used. *p <0.05**p < 0.01
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SA-FasL engineering of human PBMCs abrogates acute GVHD in a humanized
mouse model.
To extend the observed effect of SA-FasL engineering on human immune response,
we first performed in vivo tracking of human cells using NOD-scid-IL2γRnull (NSG) model.
Neutrophil depleted human PBMC were engineered with SA-FasL or SA (control protein).
NSG recipients were irradiated at 200 cGy followed by i.v injection of 5x106 SA- or SAFasL engineered human PBMCs. When analyzed 5 days post infusion, spleen of SArecipients had significantly greater number (Fig. 21A) as well as frequency (Fig. 20) of
total human cells and human T cells as compared with SA-FasL group. Importantly, we
observed a similar pattern in the liver (Fig. 21A and 20), a major target in human PBMC
induced xenogeneic GVHD. Following this observation, we established a model of acute
xenogeneic GVHD by transferring human PBMC, adapted from King et al.148. When 200
cGy preconditioned NSG animals were infused with 10 x106 human PBMC, animals
developed clinical signs of GVHD by day 14, including significant weight loss, hunched
posture, ruffled fur and reduced motion with median survival time of 15 days (Fig. 21B).
Delivery of SA-engineered human PBMCs had similar trend of developing fatal GVHD
with median survival time of 15 days (Fig. 21B). However, engineering the human PBMCs
with SA-FasL before transfusion significantly extended the survival (p<0.0001) with
27.67% of animals surviving for >60 days (Fig. 21B). There was a significant delay in the
onset of GVHD with significant body weight loss by day 25 as compared with day 13 for
the SA group. Taken together, these data suggest that engineering alloreactive T cells with
SA-FasL is an efficient strategy to eliminate pathogenic cells to mitigate fatal acute GVHD
in a xenogeneic humanized NSG model.
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Figure 20. Frequency of human immune cells recovered from preconditioned NSG
animals. Preconditioned (200 cGy) NSG animals were transplanted with SA or SA-FasL
engineered human PBMC. After 5 days post transplantation, spleen and liver of NSG
recipients were analyzed for human immune cells by flow cytometry. For comparison of
means, unpaired two tailed T- test was used. Data shown as mean ± SEM. *p <0.05**p <
0.01

66

Figure 21. SA-FasL engineering eliminates activated human PBMCs and abrogates
xenogeneic GVHD. (A) Absolute number of human cells recovered from preconditioned
NSG animals. NSG animals were preconditioned at 200 cGy and SA or SA-FasL
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engineered neutrophil depleted PBMCs were i.v injected. After 5 days post injection,
spleen and liver were analyzed by flow cytometry. Data pooled from three independent
experiments. (B) Xenogeneic GVHD is prevented from SA-FasL engineered PBMCs.
Preconditioned NSG animals (200 cGy) were transplanted with unmodifed or SA/SA-FasL
engineered human PBMC. Animals were followed for development of xenogeneic GVHD.
For comparison of means, unpaired two tailed t-test was used in (A). For survival curve
comparison log-rank (Mantel Cox) test was used. Data shown as mean ± SEM. *p <0.05**,
p < 0.01, ***p < 0.001, ****p <0.0001
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Discussion
Despite various preventive strategies being implemented in the clinic for
modulation of pathogenic function of alloreactive donor T cells, significant incidence of
acute GVHD remains a challenge and limits the broad application of HSCT as a therapeutic
modality for various disorders. Clinically, the major challenge is to reduce the severity of
GVHD without simultaneously compromising the beneficial effects of T cell mediated
immune responses. We herein describe a novel strategy to physically deplete alloreactive
T cells in vivo as an effective means of preventing acute GVHD in a mouse model
simulating HSCT in haploidentical clinical setting. We employed Fas/FasL mediated
AICD as a strategy to specifically purge out alloreactive T effector cells to prevent acute
GVH. AICD via Fas/FasL pathway is an important homeostasis mechanism to limit clonal
expansion of activated T cells at the down phase of immune responses. AICD has been
demonstrated in human and murine T cells following activation and plays a vital role in
the maintenance of peripheral T cell tolerance35,36,128,159. Mature T cells acquire specific
AICD susceptibility after prolonged activation and are dependent on repetitive TCR
engagement with the antigen and cell cycle progression, thus spearing resting T
cells34,136,160. Using the ProtExTM platform technology pioneered in our lab145, we
engineered donor T cells to transiently display on their surface a novel from of the Fas
death ligand, FasL, molecule chimeric with a modified form of streptavidin, SA-FasL.
Our collective results show that this strategy efficiently depletes activated alloreactive T
cells, resulting in the prevention of lethal acute GVHD in an allogeneic and a humanized
mouse model.
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T cells were effectively engineered with SA-FasL and underwent apoptosis
following activation by alloantigens both in vitro and in vivo. Coculture of SA-FasLengineered alloreactive T cells with unmodified cells in a mixed lymphocyte in vitro study
demonstrated that apoptosis occurs primarily through an autocrine fashion by engagement
of SA-FasL with Fas receptor on the same T cells. Importantly, SA-FasL was effective at
femtogram levels in the elimination of alloreactive T effector cells in vivo.

These

observations are consistent with reports by others demonstrating that membranous, but not
soluble, FasL is effective in the induction of apoptosis by crosslinking Fas receptor161. Our
published and unpublished studies in solid organ and islet transplantation models129-131
using SA-FasL also corroborate the present findings. Interestingly, SA-FasL also
eliminates donor Treg cells in our model. A study by Fritzsching et al.144 demonstrated
that freshly isolated naive Treg cells (CD4+CD25+FoxP3+) have higher susceptibility to
Fas-mediated apoptosis post TCR restimulation confers resistance to Fas-mediated
apoptosis in contrast to T effector cells. This suggest that SA-FasL on Treg cells provides
apoptotic signals early on before this cell population being activated, whereas SA-FasL
deliver apoptotic signals in T effector cells after TCR activation.
We then established a clinically relevant parent (C57BL/6, H-2b) to F1
(C57BL/6xBALB/c, H-2b/d) haploidentical HSCT model. In as much as transplantation of
whole bone marrow cells into a lethally irradiated mouse does not develop GVHD, unlike
rats and humans, we admixed bone marrow cells with autologous splenocytes and
demonstrated the transplantation of this cell mixture from C57BL/6 into lethally irradiated
F1 recipients resulted in acute GVHD. Using this model, we demonstrated that donor cells
containing splenocytes engineered with SA-FasL was effective in preventing acute GVHD,
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whereas all mice receiving SA control protein engineered cells showed classical signs of
GCHD, including hunched posture, decrease in mobility, ruffled fur and skin rashes along
with diarrhea, and succumbed to acute GVHD and expired. As a prelude to clinical
translation of this approach, we also demonstrated that human T cells engineered with SAFasL underwent apoptosis in response to mouse xenoantigens in vivo that resulted in
significant protection against acute GVHD.
Alloreactive T cells mediated destruction of primary and secondary lymphoid
organs is a good indicator of acute GVHD and is responsible for the lack of immune
reconstitution following HSCT in conditioned recipients162. Inefficient immune
reconstitution contributes to frequent opportunistic infections and relapse. When long term
surviving animals (>100 days) were analyzed for immune composition, they were fully
donor chimeric with efficient engraftment and better frequency of immune cell components
as compared with long term surviving animals that received only bone marrow cells, but
not GHVD causing spleen cells. Efficient immune competency was further confirmed by
demonstrating that long term survivors rejected third party, but not those animals that
received donor skin allografts. These findings also indicate that SA-FasL selectively
purges out alloreactive T cells, leading to systemic tolerance to donor alloantigens, but
preserves non-alloreactive T cells so that they generate an effective immune response to
donor-unrelated antigens.
Clinical GVHD involves significant target tissue tropism that includes recognition
of either major or minor histocompatibility antigens followed by proliferation in lymphoid
organs and target tissue infiltration resulting in significant tissue damage. Multiple studies
suggest that the GVHD progression is highly time sensitive. Allogeneic T cell activation
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occurs in several lymphoid organs at early time point (afferent phase day 6) followed by
dramatic expansion of effector T cells163,164. Activation of alloreactive T cells occurs in
draining lymph nodes rather than peripheral lymph nodes. Clinical significance is
supported by the inability of memory T cells to induce lethal acute GVHD165, despite their
ability to alloreactivity as naïve T cells. Furthermore, CD62L+ Treg, but not CD62L- , cells
are capable of suppressing acute GVHD in vivo, despite both cells being able to suppress
alloreactive T cell proliferation in vitro166,167. Study by Nguyen et al.167 suggested that
alloreactive T cells had similar pattern of early activation, proliferation and localization
with respect to Treg cells. However, persistent BLI (bioluminescence imaging) signals
indicated that proliferation of alloreactive T cells continued to increase in lymphoid tissues
and target organs in parallel with development of signs of GVHD. In addition, they show
that Treg cells as cellular therapy to prevent acute GVHD is time and dose dependent, such
that earlier infusion of Treg cells led to greater reduction of effector T cells proliferation
and better survival. The observed protective effect is dose dependent requiring higher doses
of Treg cells to reverse established inflammation. In our study, SA-FasL engineering
induced apoptosis of alloreactive T cells post infusion, thus significantly reducing their
number and thereby limiting their proliferation. When analyzed at day 21 post
transplantation (effector GVHD phase), SA-FasL-spleen cells recipient had significantly
less activated CD4+ and CD8+ T cells, but these animals also had substantially less Treg
cells. The Treg/T effector ratio is a critical determinant of suppression; however, SA-FasLspleen and unmanipulated spleen recipients had similar level of Treg/activated T effector
ratios. However, the depletion of donor Treg cells before transplantation negated the
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beneficial effect of SA-FasL, providing direct evidence that Treg cells play a critical role
in our model.
The source of discrepancy between the transplantation of Treg-depleted cells and
phenotyping at day 21 post-transplantation in our model is unknown and may be due to
several factors. First, FoxP3 as a canonical marker of Treg cells does not define their
regulatory capacity.

Treg cells show plasticity dictated by the nature of the

microenvironment they function in. In particular, Treg cells can assume pathogenic
functions in response to excessive inflammation. IFN-γ has been shown to limit Treg cell
function168 and acute GVHD is characterized by a highly inflammatory state. Expression
of FoxP3, a master regulator of Treg cells, alone is not adequate for functional stability.
The suppressive function of these cell population is well correlated with DNA methylation
status of FoxP3 CNS2 region169. Acute GVHD has been considered a Th1-type disease
dominated by cytotoxic T cell mediated pathology with increased production of Th1
cytokines. When analyzed by qRT-PCR, SA-FasL-spleen recipients had significantly less
Th1 phenotype (T-bet, IFN-γ, TNF-α) and other proinflammatory mediators (IL-6) than
control groups. Instead, SA-FasL-spleen recipients had skewed differentiation with
upregulated IL-4, GATA-3 and RORγt. This is in line with previous reports demonstrating
that the depletion of alloreactive Th1 T cells by AICD polarizes the residual CD4+ T cells
to a Th2 phenotype, which may protect against acute GVHD52,170. Treg cells has been
implicated in therapeutic role to prevent acute GVHD. However, significant number of
Treg cells needs to be infused and multiple experimental protocol for ex vivo expansion of
donor Treg cells are under trial53,171. Interestingly, CD25+ Treg cells were still
indispensable in the preventive strategy despite the significant elimination of alloreactive
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cells in vivo. This observation is similar to the high dose post-transplant cyclophosphamide
strategy that requires Treg cells for its preventive effect172.
In conclusion, we demonstrate human and mouse T cells can efficiently be
engineered with SA-FasL protein in a practical and clinically applicable manner and that
this strategy is effective in preventing acute GVHD in two clinically relevant settings,
myeloablative haploidentical and humanize mouse models. Engineering donor graft with
SA-FasL provides efficient, attractive and facile means of modulating immune response to
prevent lethal acute GVHD with significant translational potential.
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CHAPTER 3
PANCREATIC ISLETS SURFACE ENGINEERED WITH CD47 INNATE IMMUNE
CHECKPOINT SHOW ENHANCED ENGRAFTMENT FOLLOWING
INTRAPORTAL ISLET TRANSPLANTATION

Introduction
Islet transplantation is an important β-cell replacement therapy for refractory
chronic pancreatitis and type 1 diabetes (T1D). A major limitation to clinical beta cell
replacement therapy is a significant loss of islets immediate post-transplantation triggered
by instant blood mediated inflammatory reaction (IBMIR)173,174. IBMIR is initiated when
islets come into direct contact with the recipient blood following intraportal infusion and
is responsible for the loss of 50-70% of the initial islet mass175,176. IBMIR is characterized
by the activation of coagulation cascade, complement activation, and infiltration of
myeloid cells that express various inflammatory mediators that result in the destruction of
islets80,84.

Tissue factor (TF) and various other proinflammatory cytokines and

chemokines, such as IL-1, IP-10, IL-6, CXCL8, CXCL10, CCL2, expressed by islets or
resident antigen presenting cells trigger IBMIR79,84,88,177,178. As such, insulin independence
rate for autologous islet transplantation at 5 years can be as low as 10% and multiple
infusions of islets from different donors may be required to achieve insulin independence
in recipients of allogeneic islet grafts179,180. Therefore, effective control of IBMIR will
overcome an important limitation of clinical islet transplantation.
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CD47 is a ubiquitously expressed transmembrane glycoprotein of the
immunoglobulin superfamily that serves as a ligand for the signal regulatory protein alpha
(SIRPα), an immune inhibitory receptor, expressed on the surface of myeloid cells119. The
interaction of CD47 with SIRPα serves an important innate immune checkpoint that
delivers a “don’t-eat-me” signal and acts as a critical regulator of “marker of self”119. The
importance of CD47/SIRPα axis in self-recognition and inhibition of phagocytosis by
macrophages was demonstrated by rapid clearance of red blood cells genetically modified
to lack CD47 expression following infusion into CD47 competent syngeneic mice110.
CD47-SIRPα pathway has been implicated in the regulation of both innate and
adaptive immune responses. The system negatively regulates macrophage activation and
phagocytosis119, adhesion and activation of platelets and neutrophils116, attenuation of
antibody-dependent cell-mediated cytotoxicity/phagocytosis (ADCC/ADCP)181,182, and
adaptive immune responses183-185. These functional features of CD47 were shown to be
extensively exploited for immune evasion by various tumors that highlighted the potential
of CD47-SIRPα axis as an important target for cancer immunotherapy186. Indeed, various
tumor cells were shown to have elevated levels of CD47 expression and its blockade using
antibodies resulted in effective therapy in preclinical cancer models that led to current
efforts to test this innate immune checkpoint blockade for cancer immunotherapy in the
clinic186-189.
CD47/SIRPα pathway has been shown to play a critical role in innate allo- and
xeno-recognition, independent of adaptive immunity190,191. Polymorphism in the SIRPα
that alters the binding strength of CD47 is associated with rapid clearance of various
cellular grafts, including hepatocytes120,185, insulinoma cells192, and hematopoietic stem
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cells108,193,194.

Ectopic expression of recipient CD47 in porcine cells blocks their

phagocytosis by human macrophages195. Similarly, hematopoietic cells from swine
genetically modified to express human CD47 showed enhanced engraftment in a
humanized mouse model of transplantation196.
Given the demonstrated role of CD47-SIRPα axis as innate immune checkpoint,
we hypothesized that CD47 can be used to enhance syngeneic islet engraftment by
mitigating IBMIR. We herein report the generation of a novel form of SA-CD47 molecule
and demonstrate for the first time that that the transient display of CD47 protein on the
surface of islets enhance engraftment and long-term function in a minimal mass intraportal
islet transplantation mouse model by mitigating IBMIR. The rapid and transient display
of SA-CD47 protein on the surface of tissues and cells to mitigate IBMIR provides a facile
and clinically applicable platform with significant translational potential for transplantation
of various tissue and cellular grafts.

Materials and Methods
Animals
C57BL/6 (CD45.2, H2Kb) mice were purchased from Jackson Laboratory. Animals were
bred and maintained in our specific pathogen-free animal barrier facility at the University
of Louisville, KY. All experiments were performed in accordance with the policies of the
NIH for Guide for the Care and Use of Laboratory Animals and protocols approved by the
University of Louisville Animal Care and Use Committee.
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Construction, production, and physical characterization of SA-CD47 protein
A synthetic gene encoding the extracellular domain of CD47 (19-161 bp; GI: AB012693.1)
of C57BL/6 murine strain was subcloned C-terminus to a modified form of streptavidin in
the drosophila pMT/BiP/V5-His CuSO4-inducible expression vector (Fig. 1)145.
Drosophila S2 cells were transfected with the construct using the Celfectin II transfection
system (Invitrogen) to establish stable transfectants. SA-CD47 expression was induced
using 1 mM CuSO4, culture medium was collected 3 days later, and the protein was purified
using a metal-ion charged sepharose column taking the advantage of the 6xHis tag
engineered into the C-terminus (GE, Amersham). Purified protein was characterized using
SDS-PAGE and Western blot analysis per published protocols130,145.

Cell surface engineering with SA-CD47 protein
Spleens from C57BL/6 or Lewis rat were harvested and processed into single-cell
suspension using frosted slides. Red blood cells were lysed using a home-made buffered
ammonium chloride solution. SA-CD47 engineering of spleen cells was done following
previously reported protocol131. Cell surface was modified with biotin by incibation in 5
µM EZ-LinkTM Sulfo-NHS-LC biotin (hereafter referred to as biotin) solution (Pierce) in
sterile PBS at room temperature for 30 mins. Cells were then washed twice with sterile
PBS followed by incubation with 200 ng SA-CD47 or an equimolar amount of SA protein
per 106 cells at a final volume of 500 µl of sterile PBS for 30 mins in a cold room by
constant rocking. Cells were then washed and analyzed for the presence of biotin and SACD47 on the cell surface by staining with streptavidin-allophycocyanin (APC) and APClabelled anti-mouse CD47, respectively, using flow cytometry.
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In vitro phagocytosis assay
In vitro phagocytosis assay was done as described before112,183. Briefly, SA- and SA-CD47
engineered rat spleen cells were labeled with 2.5 μM carboxyfluorescein succinimidyl ester
(CFSE, Thermo Fisher Scientific) or 2.5 μM Cell Trace Violet (CTV, Thermo Fisher
Scientific), respectively, according to manufacturer’s protocol and resuspended in
complete RPMI (RPMI 1640 supplemented with 10% FBS, Penicillin/ Streptomycin and
2 mM L-Glutamine). For single culture assay, SA-rat spleen cells or SA-CD47-rat spleen
cells (2.5 X 106/ well) were cultured with mouse RAW 264.7 macrophage-like cell line
(0.5 X 106/well). For mixed culture settings, both fluorescence labeled target cells were
mixed in a 1:1 ratio followed by co-culture (2.5 X 106 cells/well) with RAW 264.7 cells
(0.5 X 106/well). Post incubation non-engulfed cells were washed, and adherent RAW cells
were harvested and stained with anti-CD11b antibody prior to flow cytometric analysis.
Phagocytosis assessed by measuring % of double positive macrophages (CD11b+ CFSE+
or CD11b+ CTV+).

Pancreatic islet isolation, engineering, and functional analysis
Islet isolation was performed using LiberaseTL enzyme (Roche) according to a standard
protocol128,130. Islets were engineered with the SA-CD47 or SA as a control protein by
incubating first in 5 μM biotin then with the indicated amount of protein for 30 mins130,145.
Alamar blue (AB, Thermo Fisher scientific) assay, that incorporates redox reagent that
changes color when reduced in response to metabolic activity, was used to assess the effect
of SA-CD47 engineering on viability and metabolic activity of islets197. Briefly, 100
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unmodified naïve or SA-CD47-engineered islets were cultured in complete RPMI media
supplemented with 10% AB reagent in a 96-well plate. After 6 hours of incubation, the
reduced form of reagent soluble in the solution was measured as absorbance at a
wavelength of 562 nm on SpectraMax microplate reader (Molecular Devices).

Glucose-stimulated insulin secretion (GSIS) assay
A static incubation protocol for GSIS assay was performed to assess whether engineering
with SA-CD47 impacts islet function. Naïve islets or SA-CD47-engineered islets (100
islets per transwell) were incubated at 3 mM glucose solution, prepared in Krebs ringer
bicarbonate buffer, for 1 hour for equilibration in a transwell (Millicell, Merck). The
transwell was then drained and transferred to a new low glucose solution well, incubated
for 1 hour, and the solution was collected as low-glucose insulin secretion. The transwell
was then transferred to a high glucose solution (11 mM) well, incubated for 1 hour, and the
solution was collected as high-glucose insulin secretion. The insulin content was analyzed
by murine insulin ELISA kit (Mercodia). The stimulation index (SI) was calculated as a
ratio of insulin secreted in high to low glucose stimulation.

Pancreatic islet transplantation and glucose tolerance test
The impact of SA-CD47 on the modulation of IBMIR and islet engraftment was assessed
in a minimal mass intraportal model. Four days before transplantation, male C57BL/6
mice (10-14 wks-old) were rendered diabetic by single intravenous injection of
streptozotocin (200 mg/kg, Sigma-Aldrich). Blood glucose level were obtained using a
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portable glucose meter (Roche, AccuCheck). Animals with two consecutive non-fasting
blood glucose readings of > 250 mg/dl were considered diabetic and used for intraportal
transplantation. Each diabetic recipient was transplanted with 125 SA- or SA-CD47engineerd islets via portal vein. Animals were monitored for blood glucose levels twice a
week. Long-term graft recipients with normoglycemia were subjected to a standard
intraperitoneal glucose tolerance test (IPGTT).

Briefly, animals were injected

intraperitoneally with glucose bolus (2 mg/kg) after 6 hrs of fasting and monitored for
blood glucose levels at various time points (0, 10, 20, 30, 45, 60, 90, 120, 150 mins). Naïve
C57BL/6 mice were used as controls for IPGTT.

Isolation of intrahepatic immune cells
Intrahepatic immune cells were isolated using mechanical disruption as previously
described198. Briefly, after euthanasia, cardiac perfusion was performed with 10 ml of
sterile, cold saline. Mechanical disruption was done using frosted slides (in HBSS)
followed by repeated passing through a18-G needle. The suspension was centrifuged at
500 rpm for 1 min and supernatant was transferred to a new tube and centrifuged at 1400
rpm for 10 min. The pellet was resuspended in complete RPMI, filtered, and processed for
flow cytometry analysis.

Flow cytometry and antibodies
The optimal concentration for all fluorochrome-conjugated antibodies was determined by
titration. Antibodies clones specific against mouse CD45.2 (eBiosciences, 12-0454-82),
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CD11b (BD Biosciences, 550993), Ly6C (Biolegend, 128036), Ly6G (Biolegend,
127606), F4/80 (Biolegend, 123122), Gr1 (eBiosciences, 48-5931) were used. For surface
staining, cells were first incubated with Fc blocking antibody (anti CD16/32, Biolegend)
for 10 min at 4° C followed by incubation with surface antibodies for 30 min at 4° C. The
cells were analyzed by BD LSR II and Flow jo (Tree Star, CA).
In vitro tube model of islet-blood interactions
In vitro tube model to mimic IBMIR was performed as described
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. Fresh autologous

blood was harvested and collected in heparin-coated 1.5 ml Eppendorf tubes. SA- or SACD47-engineered islets (100 islets) were mixed and incubated with 500 µl of blood
(without any additional heparin). Tubes were incubated in a rotator at 37 °C incubator for
3 hrs. Post incubation, serum was collected, and blood-islet clots were preserved in 10%
Neutral Buffered Formalin (NBF, source) followed by paraffin embedding for histological
analysis.
RNA isolation and quantitative real-time PCR
Total RNA was extracted from the liver tissues or islet-thrombus using TRIzol reagents
(Invitrogen Corporation, USA) according to the manufacturer’s instructions. Total RNA
was quantified using a NanoDrop ND-2000c spectrophotometer (Thermo Fisher Scientific,
Inc.). In addition, cDNA was reverse transcribed from total RNA (2 µg) using SuperScript
IV VILO cDNA Master Mix (Thermo Fisher Scientific, USA) with the following thermal
conditions: 25 °C 10 min; 50 °C 10 min; and 85 °C 5 min. qRT-PCR was performed using
validated TaqMan Gene Expression Assays (Table 1) according to the manufacturer’s
instruction on Quant Studio 3 RT-PCR system (Thermo Fisher Scientific. USA).
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Table 4. TaqMan gene expression assay for islet graft analysis
Gene symbol

Assay ID

F3 (TF)

Mm00438855_m1

IL1b

Mm00434228_m1

MCP-1

Mm00441242_m1

NF-KB (p65)

Mm00501346_m1

GAPDH

Mm99999915_21

HMGB1

Mm00849805_gH

Histological analysis
Paraffin-embedded clots were cut into 4 µm thickness, H&E stained, and then graded for
parameters as described199. Grade 0: intact islet morphology with uniform nuclear
distribution without any fragments/fractures. Grade 1, intact islet morphology with uniform
nuclear distribution with minimal fragments/fractures; Grade 2, disrupted morphology with
non-uniform nuclear distribution with significant fragments/fractures along with necrotic
patches; and Grade 3, significant disruption of morphology with loss in nuclei and
significant necrotic patches.
For immunohistochemical analysis, islets bearing liver sections or islets clots retrieved
from in vitro tube assay were paraffin-embedded, then sectioned at 4 µm thickness on a
microtome (Leica). The sections were dewaxed and processed for histological evaluation
as reported87,90,199. Sections were stained with anti CD11b (Novus biologicals, NB600-137)
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or anti-insulin (Dako, A0564) or Hoechst (Molecular probes, H-3570). Fluorescent images
were obtained using a Leica confocal microscopy.

Statistical analysis
All data sets were analyzed using Graph pad prism v.7 (GraphPad Inc. CA) and expressed
as mean ± SEM. Mean comparison between the groups was performed by using Student’s
t-test. Survival curves were compared using the Log-rank test (Mantel-Cox) statistical
method. p < 0.05 was considered significant.

84

Results
Generation and characterization of chimeric SA-CD47 protein
Transient and positional display of recombinant protein ligands to immune
receptors on the cell surface provides a practical and potentially safe alternative to ectopic
gene expression for immunomodulation. We have developed the concept of generating
recombinant immunological ligands with a modified form of core streptavidin and their
transient and positional display on the surface of biotinylated cells and tissues for
immunomodulation with demonstrated efficacy in autoimmunity, transplantation, and
cancer settings129,200-204. Using this scheme, we herein designed a synthetic gene encoding
the extracellular domain of mouse CD47 (aa 19-161), required for binding and signal
transduction through SIRPα, and a modified form of core streptavidin (SA). The chimeric
gene was cloned into the Drosophila copper sulfate-inducible pMT/BiP/V5-HisA
expression vector with an N-terminal secretion signal sequence (BiP) and a hexahistidine
tag (6xHis; Figure 22A). Drosophila S2 cells stably transfected with the construct used
for protein expression and purification using a metal affinity chromatography as we
reported previously129. SA-CD47 was run as a ~37 kDa protein in denaturing SDS-PAGE
when the samples were heated at 100o C and as > 250 kDa oligomers without heat treatment
(Figure 22B), consistent with the reported structural feature of native streptavidin145.
Western blot analysis using anti-SA antibody confirmed the identity of the protein (Figure
22C).
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Figure 22. Cloning, expression, and structural characterization of SA-CD47 protein.
(A) Schematic representation of SA-CD47 construct. A synthetic chimeric gene encoding
the extracellular domain of mouse CD47 N-terminus to core streptavidin (SA) with flexible
linkers and a 6xHis tag to facilitate protein purification was subcloned into the CuSO4inducible pMT-Bip-V5-HisA S2 insect cell expression vector. (B) SDS-PAGE profile of
the purified SA-CD47 protein. The protein was purified from culture supernatant of S2
stable transfectants using immobilized metal affinity chromatography and analyzed using
SDS-PAGE after heating the samples at 100 oC (H) or without heat (NH). (C) Western blot
profile of SA-CD47 using antibodies against streptavidin. The SA-CD47 chimeric protein
runs as a single monomeric band (~ 37 kDa) with heat and as oligomers (> 250 kDa)
without heat.
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Effective engineering of islets with SA-CD47 protein without negatively impacting
their viability or function
We next employed engineering of mouse spleen cells as a flexible and quantitative
platform to assess the function of streptavidin domain of chimeric SA-CD47 protein for
binding biotinylated surfaces145. Mouse spleen cells were first modified to attach a reactive
biotin to the cell surface through NHS ester crosslinking followed by engineering with
various concentrations of the SA-CD47 protein. There was a dose-dependent attachment
of SA-CD47 to the surface of biotinylated cells that reached a plateau at 320 ng protein/106
cells (⁓ 99 % of live cells with a mean MFI of 6260) as assessed by flow cytometry (Figure
23 and 24A).
We next tested if pancreatic islets can be engineered with SA-CD47 without a
detrimental effect on islet viability and function. C57BL/6 mouse islets were surface
modified with biotin (5 μM) followed by engineering with SA-CD47 protein (400 ng/125
islets). Confocal microscopic analysis of islets using an anti-CD47 Ab demonstrated dense
display of the protein on the surface (Figure 24B). Islets were analyzed for viability and
metabolic activity using Alamar Blue (AB) assay to ensure the lack of a detrimental effect
due to SA-CD47 engineering. Viable and metabolically active cells reduce resazurin, a
component of AB, to resorufin by mitochondrial enzymes197. The degree of redox reaction
is an indicator of the metabolic activity of viable cells197. After incubation for 6 hrs in AB,
there was no significant difference in the level of reduced resorufin between SA-CD47engineered islets and unmodified control islets (Figure 24C), demonstrating lack of a
detrimental effect causing by engineering. This observation was further corroborated with
FDA/PI viability assay performed 24 hr post-engineering. Confocal microscopy analysis
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revealed that the majority of SA-CD47-engineered islets (> 90%) were intact and viable as
indicated by bright FDA staining (Figure 24D).

Engineered islets were also

morphologically intact without any hypoxic centers (Figure 25). GSIS assay also showed
comparable levels of functional fitness between SA-CD47-engineered islets and
unmodified control islets in insulin secretion (Figure 24E). Importantly, no difference in
stimulation indices of SA-CD47-islets and unmodified islets were observed (Figure 24E).
Taken together, these results demonstrate that pancreatic islets can be efficiently
engineered to display the SA-CD47 protein on their surface without a negative impact on
their viability, metabolic activity, and insulin secretion function.
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Figure 23. Representative histogram overlay plot of spleen cells engineered with SACD47 protein. Spleen cells were biotinylated (5 µM) and then engineered with SACD47 protein at the indicated concentrations (ng protein/106 cells). Histograms in color
show the fluorescence intensity (MFI) at respective engineering levels.
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Figure 24. Effective engineering of islets with SA-CD47 protein without a negative
impact on their viability or function. (A) Assessment of cell surface engineering with
SA-CD47 protein. Spleen cells were biotinylated in 5 μM EZ-Link Sulfo-NHS-LC-Biotin
followed by engineering with the indicated amounts of the SA-CD47 protein (ng/106 cells).
The levels of chimeric protein on the cell surface was assessed using an anti-CD47
antibody in flow cytometry. The MFI values as a function of protein concentrations from
three independent experiments are graphed (B) Representative image of islet engineered
with SA-CD47 protein. Mouse islets were biotinylated (5 μM) followed by engineering
with SA-CD47 protein (400 ng/125 islets). The levels of biotin and CD47 molecules were
assessed using SA conjugated PE (SA-PE; green) and an antibody against CD47 (antiCD47 APC; red), respectively, in confocal microscopy. (C) Engineering with SA-CD47
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protein does not impact islet viability and metabolic activity. SA-CD47-engineered islets
(SA-CD47-islet) or unmodified naïve islets (Islet) were incubated with alamar blue reagent
for 6 hours at 37°C. The level of alamar blue reduction was measured as absorbance at 562
nm. Data are from two independent experiments. (D) FDA/PI viability test showing lack
of a detrimental effect of engineering on islets. Representative live/dead confocal
microscopy images of unmodified and SA-CD47-engineered islets 24 hours post
engineering (green = live; red = dead). A total of 47 unmodified (Islet) and 40 engineered
(SA-CD47-islet) islets were analyzed for viability. (E) Glucose-induced insulin secretion
assay showing functional fitness of SA-CD47-engineered islets. Data expressed as mean ±
SEM. For comparison of means, an unpaired t-test was used for C, D and E. ns, not
significant.
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Figure 25. Bright field images showing integrity of SA-CD47-engineered islets.
Unmodified (control, left) and SA-CD47-engineered islets (right) were cultured for 24
hours post engineering and then imaged.
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SA-CD47-engineered xenogeneic cells are refractory to phagocytosis by
macrophages.
CD47 expressed on autologous cells deliver a “don’t eat me” signal through SIRPα,
a negative regulator of phagocytosis, expressed on macrophages and dendritic cells119.
Interaction of CD47 with SIRPα is species-specific and dictates the phagosome
formation205. Thus, we assessed the anti-phagocytic function of SA-CD47 in a standard
xenogeneic in vitro phagocytosis assay112,183. Rat splenocytes were engineered with SACD47 or SA as a control protein (Figure 26A) and then labeled with the fluorescence dyes
CTV or CFSE, respectively.

Coculturing these cells with the mouse RAW 264.7

macrophage cell line demonstrated significant (p = 0.0088) phagocytosis of SA-engineered
rat cells over SA-CD47-engineered cells (Figures 26B and 27). To further corroborate this
observation, we performed competitive phagocytosis assay in mixed culture settings where
RAW 264.7 cells were co-cultured in the presence of both target cells labelled with
different fluorescence dyes. Mouse macrophage preferentially phagocytosed SA-rat spleen
cells (Figures 26C and 27). Collectively, these results demonstrate that the SA-CD47
protein is functional and when displayed on target cells prevents phagocytosis by
macrophages.
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Figure 26. SA-CD47 protein on xenogeneic cells prevents phagocytosis by
macrophages. (A) A representative histogram of rat splenocytes engineered with the SACD47 protein. Rat splenocytes engineered with the SA-CD47 protein (200 ng/106 cells)
were analyzed using an antibody against mouse CD47 in flow cytometry (dark line open
histogram) with unmodified cells (gray shaded histogram) serving as control. (B) SACD47 inhibits phagocytosis of rat splenocytes by macrophages. Mouse RAW 264.7
macrophage cells were cultured with CFSE-labelled SA-engineered rat splenocytes or
CTV-labelled SA-CD47-enginered rat splenocytes at 1:5 ratio. After 18 hours of
incubation, cells were analyzed by flow cytometry by gating on CD11b+CFSE+ or
CD11b+CTV+ as percent phagocytosis. (C) Assessment of phagocytosis in mixed cultures.
Rat cells engineered with SA and SA-CD47, and labelled with CFSE and CTV,
respectively, were mixed at 1:1 ratio and then co-cultured with RAW 264.7 cells under the
same conditions for (B). Phagocytosis of rat cells by macrophages was assessed using flow
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cytometry. Data shown as mean ± SEM of three independent experiments. *p <0.05, **p
<0.01; two-tailed unpaired t-test.

Figure 27. Representative flow plots of in vitro phagocytosis assay. SA-CD47engineerd rat splenocytes (CTV labelled) are more refractory to phagocytosis by mouse
macrophages as compared with SA-engineered cells in single or competitive mixed culture
settings.
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SA-CD47 protects islets and prevents intra-islet infiltration of CD11b+ cells in an in
vitro loop assay.
First, to understand the potential role of CD47 in protection of islets from IBMIR
mediated destruction, we performed a modified in vitro loop assay for islet-blood
interaction 173. Engineering with SA-CD47 did not prevent fibrin deposition or thrombosis
after incubation with blood. However, histological analysis of the islet-thrombus revealed
relatively intact SA-CD47-engineered islets, whereas SA-engineered islets had significant
(p = 0.0128) destruction (Figure 28A). Intact islets with regular morphology with uniform
distribution of nuclei (Grade 0) were more common in SA-CD47-engineered islets (40%)
as compared with the SA-engineered control group (25%) (Figure 28A). SA-engineered
group had more Grade 2 islets with disrupted morphology with necrotic centers and Grade
3 islets with highly disrupted morphology as compared with SA-CD47-engineered group
(Grade 2: 25% vs. 18%; Grade 3: 24% vs. 11%). Immunofluorescence analysis of isletthrombus sections demonstrated significantly (p = 0.0244) higher infiltration of CD11b+
cells in SA-engineered islets as compared with SA-CD47 group (Figure 28B and 29).
Collectively, these results show that SA-CD47 protects islets from IBMIR mediated
disruption, potentially by inhibiting the intraislet infiltration of inflammatory cells.
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Figure 28. SA-CD47 engineering protects islets from destruction by IBMIR in an in
vitro loop assay. (A) Histological grading of islets 3 hours post in vitro loop assay indicates
SA-CD47-engineered islets are protected from blood mediated destruction as compared
with SA-engineered control islets. Frequency distribution between the groups was
analyzed by chi-square test. (B) Immunofluorescence analysis for intra-islet CD11b+
inflammatory cells. SA-CD47-engineered islets had significantly less infiltration of
CD11b+ granulocytes/macrophages as compared to SA-engineered islets. Data pooled
from three independent experiments and represented as mean ± SEM. Data means
compared by unpaired two-tailed t-test. * p < 0.05.
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Figure 29. Representative confocal images for CD11b negative staining. Tissue
sections were stained with Hoechst, insulin but without CD11b for specificity of anti
CD11b antibody (scale bar = 50 μm).
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SA-CD47-engineered islets show enhanced engraftment and function following
intraportal transplantation
Instant blood-mediated inflammatory reaction (IBMIR) occurs following the
exposure of islet grafts to recipient blood and is responsible for 50-70% of islet loss
immediate post intraportal transplantation79,173. Phagocytes play an important role in
IBMIR80,84,87,173. To assess the impact of SA-CD47 as an inhibitor of phagocytosis on islet
engraftment and long-term function, C57BL/6 islets were engineered with SA-CD47 or
SA as a control protein and used for intraportal transplantation in a syngeneic marginal
mass (125 islets) model (Figure 30A). Seven out of 8 mice (87.5%) transplanted with SACD47-engineered islet graft showed engraftment and long-term function as assessed by
blood glucose levels as compared with 1/7 (14.28%) of the SA-engineered islet graft
recipients (p = 0.0088; Figure 30B, C and 31). The average days required for achieving
normoglycemia was 17.86 ± 4.9 (mean ± SEM) in SA-CD47-islet recipients.
Intraperitoneal glucose tolerance (IPGTT) test showed significantly rapid glucose
clearance in long-term (>80 days) recipients of SA-CD47-engineered as compared with
SA-engineered islet grafts (Figure 32A). Indeed, long-term SA-CD47-engineered islet
graft recipients had a glucose clearance response comparable to naïve animals with a
similar area under the curve (Figure 32B). Histological analyses demonstrated insulinsecreting functional islet mass in long-term recipients (Figure 32 C and D). Collectively,
these results demonstrate that the transient display of SA-CD47 protein on islet surface
significantly enhance engraftment and long-term function following intraportal
transplantation.
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Figure 30. Surface display of SA-CD47 protein significantly improves pancreatic islet
engraftment and function in a syngeneic marginal mass intraportal transplantation
model. (A) Study design for intraportal islet transplantation. Animals were monitored for
blood glucose levels (BGL) post-transplantation and two consecutive daily readings of
glucose ≥ 250 mg dl–1 was considered as engraftment failure. (B) Kaplan-Meier analysis
between the groups shows significantly higher rate of post-transplant normoglycemia in
chemically diabetic recipients of SA-CD47-enginered as compared with SA-engineered
control grafts. Statistical difference assessed using log-rank (Mantel-Cox) test with **p
<0.01. (C) Non-fasting blood glucose level of transplant recipients in (B).
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Figure. 31. SA-CD47 engineering improves the intraportal islet transplantation
outcome. STZ induced (200 mg/kg) diabetic animals were transplanted with islets
engineered with SA (A, n=7) or SA-CD47 protein (B, n=8). Animals were monitored for
blood glucose levels (mg/dl) post transplantation. Grey shaded area indicates the
euglycemic region (BGL < 250 mg/dl).
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Figure 32. SA-CD47-engineered islet grafts show long-term survival and function
following intraportal transplantation. (A) Intraperitoneal glucose tolerance test shows
functional islet mass in long-term (>80 days) recipients of SA-CD47-engineered islet
grafts. SA-CD47-engineered islet graft recipients (blue) were able to regulate blood
glucose at levels comparable to age-matched naïve animals (green). In marked contrast,
SA-engineered islet graft recipients (red) failed to regulate blood glucose levels following
intraperitoneal glucose challenge. (B) Area under the curve analysis for (A). (C, D)
Histological analyses showing insulin positive islets in the liver of long-term graft
recipients. Representative H&E (C) and immunofluorescence staining (D) of liver tissues
of long-term recipients of SA-CD47-engineered islet grafts. Nuclei are stained with
Hoechst (blue) and β-cells with anti-insulin antibody (red). Data mean comparison was
done by two-tailed unpaired t-test for B. Shadow indicate SEM; ns, not significant.
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SA-CD47 display alters the intrahepatic infiltration of inflammatory cells and
inflammatory mediators.
One of the characteristic features of IBMIR mediated early loss of islets is the
recruitment of inflammatory myeloid cells into the site of engraftment87,97. To test whether
SA-CD47 on the surface of islets protect them from IBMIR mediated destruction, livers of
graft recipients were analyzed using flow cytometry to assess intrahepatic inflammatory
infiltrates 3 hrs post-transplantation. Livers of recipients transplanted with SA-CD47engineered islet grafts had lower numbers of inflammatory infiltrates, including CD11b+
myeloid cells, inflammatory monocytes (CD11b+ Ly6Chi/ CD11b+ Ly6Cint), neutrophils
(CD11bhi Gr1hi), and macrophages (F4/80+) as compared with SA-engineered islet controls
(Figure 33A and 34). However, when analyzed at 24 hrs post transplantation, there were
similar levels of intra hepatic inflammatory infiltrates in both SA-CD47- and SAengineered islet graft recipients. This observation is in line with previous studies reporting
appearance of inflammatory infiltrates in islet grafts as early as 15 min with massive
infiltration by 2 hrs post transplantation84,87,89.
We further analyzed the liver tissue samples by quantitative RT-PCR to assess the
expression of inflammatory mediators involved in peri-transplant islet mass loss. There
was no significant difference in transcript levels for various inflammatory mediators
between SA-CD47- and SA-engineered islet graft recipients when assessed at 3 hr post
transplantation. In marked contrast, when analyzed 24 hrs post transplantation, liver
samples from SA-engineered islet recipients had significantly higher expression of
transcripts for high mobility group box-1 (HMGB-1), tissue factor (TF), IL-1β, which are
responsible for early islet loss as compared with the SA-CD47-engineered islet group
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(Figure 33B). Although there was reduction in transcripts levels for MCP-1 and NK-κB in
the SA-CD47-engineerd islet group as compared with the SA-engineered group,
differences did not reach statistical significance. Taken together, these results show that
the presence of SA-CD47 protein on islet grafts mitigates IBMIR by reducing the
infiltration of inflammatory cells and their expression of inflammatory factors, resulting in
enhanced engraftment and sustained function.
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Figure 33. SA-CD47-islet recipients have significantly reduced infiltration of
inflammatory cells and mediators in liver following intraportal transplantation. (A)
Intrahepatic immune cells analysis 3 hr post-transplantation show substantially less
infiltration of immune cells in SA-CD47-engineered islet graft recipients as compared with
control SA-engineered islet recipients. Data points represent absolute cell number per gram
of liver pooled from two independent experiment with n = 2-3 per group. (B) RTqPCR
analysis of liver tissue samples 24 hr post-transplantation shows heightened expression of
inflammatory mediators in SA-engineered islets as compared with SA-CD47-engineered
islets. Data points represent relative expression in comparison to GAPDH pooled from two
independent experiments, each with n=2-4 per group. For comparison of means unpaired
one-tailed t-test was used in (A) and (B). *p < 0.05, **p < 0.01. Data shown as mean ±
SEM.
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Figure 34. SA-CD47-engineered islet graft recipients have substantially less intrahepatic infiltration of inflammatory cells. Data point indicates frequency of respective
cells (as frequency of total CD45.2+ cells) 3 hrs post-transplantation. Data pooled from two
independent experiments, with n=2-3 in each group, represented as mean ± SEM. *p <0.05,
**p < 0.01. For comparison of means unpaired one-tailed t-test was performed.
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Discussion
IBMIR mediated primarily by myeloid cells is responsible for significant islet mass
loss immediate post infusion into the liver174-176. Despite being transplanted from multiple
donors, the functional islet mass in insulin-independent patients is equivalent of 30% of a
non-diabetic healthy individual90. CD47/SIRPα axis is a critical innate immune checkpoint
that inhibits activation and phagocytic function of myeloid cells as a critical mechanism of
self/non-self-discrimination186. Tumor cells express CD47 on their surface as an effective
means of immune evasion and the blockade of this molecule using antibodies was shown
to galvanize innate immune responses against tumor with remarkable efficacy for the
clearance of cancer in various preclinical models186-189. In this study, we assessed whether
tumor immune evasion mechanisms can be simulated using CD47 as a means of mitigating
IBMIR. We herein report for the first time that the transient display of a novel form of this
molecule, SA-CD47, on the surface of islets results in enhanced engraftment and long-term
function in an intraportal minimal mass syngeneic mouse model. Long-term engraftment
and function were associated with peri-transplant reduced intragraft inflammatory innate
immune cells and transcripts for proinflammatory mediators.
As a practical and alternative approach to ectopic expression of CD47 in islets, we
generated a novel construct, SA-CD47, that contained the extracellular functional domain
of mouse CD47 chimeric with core-streptavidin using a previously published scheme for
FasL as a regulator of adaptive immunity129. Consistent with the structural features of
streptavidin206, SA-CD47 protein exists as oligomers and was displayed on the surface of
biotinylated cells and islets in a rapid and efficient manner taking advantage of the high
affinity interaction (Kd ~10-14 M) between biotin and streptavidin206. Importantly, the
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engineering of islets with SA-CD47 did not negatively impact their viability, metabolic
activity, or insulin secretion. These findings are consistent with our published studies
transiently displaying SA-FasL on the surface of islets for the regulation of alloreactive
immune responses204,207. In an in vitro xenogeneic system, SA-CD47-engineered rat cells
overcame phagocytosis by mouse macrophages. This observation is consistent with studies
demonstrating that porcine cells genetically modified to express human CD47 circumvent
phagocytosis by human macrophages195. Engraftment of human hematopoietic stem cells
is sensitive to SIRPα alleles expressed in mice as NOD expressing the high affinity allele
for human CD47 show better engraftment as compared with mice expressing alleles with
low affinity194. Furthermore, mouse hematopoietic stem cells were shown to transiently
upregulate CD47 on their surface in response to mobilizing cytokines and inflammatory
agents and the level of expression was directly correlated to their ability to evade
phagocytosis208.
In vitro loop assay that simulates in vivo IBMIR, that involves direct contact of
peripheral blood with islets, showed well-preserved morphology with uniform distribution
of nuclei and minimal fracture of SA-CD47-engineered islets as compared with SAengineered controls. There were significantly (p=0.0244) fewer CD11b+ cells in the isletthrombus as compared with SA-engineered islets. This result suggested that SA-CD47 can
potentially abrogate IBMIR effects. Following this observation, in intraportal islet
transplantation, islets engineered with SA-CD47 protein showed significantly enhanced
engraftment and long-term function (87.5%) as compared with SA control proteinengineered islets (14.2%) following intraportal transplantation.

These observation

provides strong evidence for the ability of SA-CD47 to mitigate IBMIR and is consistent
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with a study reporting improved engraftment of human hepatocytes transduced with the
mouse CD47 in immunodeficient mice following intraportal transplantation209. Also,
transplantation of hepatocytes from CD47 knockout mice into syngeneic wild type
recipients resulted in the activation of macrophages and poor graft survival 120. Previous
studies have shown that IBMIR is initiated immediately after islet infusion80,84,87. Rapid
platelets deposition is observed within 30 mins on the islet surface along with infiltration
of neutrophils/macrophages (CD11b+) that appear as early as 15 min post-transplantation
and peak at 2 hr87. When analyzed at 3 hrs post-transplantation, SA-CD47-engineered islet
graft recipients had significantly less intragraft inflammatory cells, particularly
inflammatory monocytes (CD11b+ Ly6Chi/Ly6Cint), neutrophils (CD11b+ Gr1hi), and
macrophages (CD11b+ F4/80+) as compared with SA-engineered controls. SA-CD47engineered islet grafts also had significantly reduced intragraft expression of
proinflammatory HMGB1, TF, and IL-1β, all have been implicated in early islet
loss79,83,210,211. These observations indicate that the presence of SA-CD47 protein on the
surface of islets protects them from IBMIR by preventing transmigration of inflammatory
cells and reducing inflammatory mediators in the graft site.
The current study offers a novel, effective, and practical strategy to ectopic
expression of CD47 for the enhancement of autologous islet engraftment and long-term
function following infusion into the liver. However, the application of this facile approach
is not limited to islets or autologous transplantation as it can be applied to any cellular auto
or allotransplantation. Although in the present study, we focused on the efficacy of SACD47 in modulating innate immune responses, CD47 has also been implicated in
regulating adaptive immune responses. CD47 interaction with SIRPα on DCs activates
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STAT3, a critical regulator of IL-6, IL-10 and IDO expression, resulting in polarization of
T cells toward a regulatory phenotype212,213. Interaction of CD47 with SIRPα expressed on
DCs inhibits their activation and impair Th1 response214. CD47 interaction with SIRPα on
DC was shown to be critical to cardiac allograft tolerance achieved by CD154 blockade
and donor-specific transfusion215.

Lack of CD47 on donor cells resulted in rapid,

alloantigen-independent activation of DCs, uncontrollable with CD154 blockade.
Furthermore, intrasplenic infusion of CD47-deficinet allogeneic hepatocytes resulted in
accelerated rejection of donor-matched skin grafts, whereas CD47-competant hepatocytes
enhanced skin allograft survival that was associated with reduced alloreactive T cell
responses, enhanced production of regulatory cytokines, IL-4 and IL-10, as well as
significant expansion of myeloid-derived suppressor cells (MDSC)216. Indeed, CD47 was
shown to play a critical role in the expansion and regulatory function of MDSC in a
costimulatory blockade-induced tolerance to kidney allografts.

The blockade of

CD47/SIRPα pathway in this model resulted in rejection of long-term tolerant kidney grafts
that was associated with overexpression of MCP-1 and inflammatory macrophage
signature217. However, it remains to be investigated if the transient display of SA-CD47
on allogeneic islets or cellular grafts is sufficient as a single agent or in combination with
a modulator of adaptive immunity, such as SA-FasL204,207,218,219, is effective in inducing
tolerance.
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CHAPTER 4
SUMMARY, IMPLICATION AND FUTURE DIRECTION

In this dissertation, we show transient display of functional chimeric proteins as a
novel immunomodulatory approach in two distinct experimental models. In chapter two,
we use previously reported novel form of FasL, SA-FasL, to engineer donor graft in
hematopoietic stem cell transplantation. In haploidentical and xenogeneic GVHD models,
we provide evidence that engineering donor graft with SA-FasL can efficiently attenuate
the GVHD causing ability of the graft, potentially by eliminating alloreactive cells. This
strategy involves relatively very short procedure and is clinically translatable. Unlike
previously reported strategies that involves ex vivo culture of donor grafts with recipient
antigens for days, this method involves very minimal modulation of donor grafts. This
strategy is highly impactable for procedures involving HSCT for leukemic patients or to
establish donor chimerism for solid organ allo-graft transplantation. However, resistance
of some T effector cells from AICD cannot be ignored. Also, SA-FasL-spleen recipients
contract GVHD at some degree and some animals recovered as such the total protection is
not 100%. This may be beneficial with respect to graft versus leukemia or graft versus
tumor effect, where GVHD at some degree is required to maintain anti-leukemia effect. In
addition, this may be important for other T cell functions like efficient engraftment and
immunity against infections.
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The proposed strategy can be modified in multiple ways to increase the impact.
First, we show that engineering whole grafts leads to significant depletion of Treg cells
without a negative impact on the efficacy of the protocol in our model. However, this may
not be the case in the clinic. To avoid this potential pitfall, our approach could be used in
combination with other clinically applied strategies, which is attractive and easily
achievable given the efficient and practical nature of engineering. For example, we have
shown that rapamycin as an immunoregulatory drug with beneficial impact on Treg cells,
works in synergy with SA-FasL in islet and heart transplantation models130,220. Rapamycin
is used widely in the clinical transplantation with great safety profile and can be used in
combination with SA-FasL engineered cells to mitigate GVHD. Alternatively, SA-FasL
can be used in combination with IL-33, another immunoregulator with beneficial effect on
Treg cells, or chemotherapy-based conditioning, such as cyclophosphamide that also
positively impacts Treg cells and extensively used for HSCT in the clinic.
On the second part of the dissertation, we report novel implication of CD47-SIRPα
axis in attenuation of IBMIR. We show that islets engineered with SA-CD47 can modulate
innate immune responses, resulting in the prevention of early islet loss, maintaining
functional islet mass, and promoting efficient engraftment. This strategy has significant
implication in islet transplant settings either in allogeneic or autologous transplantation.
This is the first study of its kind where we target innate immune cells, myeloid cells, to
modulate immune response to prevent early loss of islets due to IBMIR. To increase the
impact of the observation, allogeneic study is very important to understand if similar results
will be observed. In addition, this strategy needs to be tested with other clinically used
agents, such as heparin to assess its beneficial impact. Extensive mechanistic studies are
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warranted in autologous as well as allogeneic settings to better understand how SA-CD47
functions that will allow further refinement of this approach and its combinatorial use with
agents that may work in synergy for a better outcome. Most importantly, this approach
needs to be tested for settings involved cell transplantation, such as HSC or hepatocytes,
as a single agent and also in combination with other modulators. In this context, the
ProtExTM technology is a rather effective platform to display both SA-FasL and SA-CD47
and the implication of these both molecules on HSCT and allogeneic islet transplantation
will be important to explore.
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